1
|
Cagnin S, Martini A, Donato D, Angeli P, Pontisso P. Electronic sanitary database: a new potential tool to identify occult chronic liver disease in general population. Intern Emerg Med 2024; 19:641-647. [PMID: 38227274 DOI: 10.1007/s11739-023-03507-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 12/06/2023] [Indexed: 01/17/2024]
Abstract
Chronic liver disease (CLD) is a leading global cause of mortality, morbidity, and healthcare resource utilization. However, the burden of CLD is underestimated because the course of the disease is often asymptomatic until clinical decompensation and the development of life-threatening complications. In this study, we assessed the use of available blood tests from electronic medical records for identifying individuals with undiagnosed CLD in the general population. We analyzed a total of 202,529 blood tests obtained from 99,848 adults recorded in the Electronic Health Records of the Padova Teaching Hospital. Transaminases levels > 1.5 times the normal value indicated occult CLD, while platelet counts < 120,000/μL identified occult cirrhosis. We characterized patients using Italian Medical Exemptions (IME), excluding oncologic cases. Overt and occult cirrhosis prevalence was 1% and 4.18%, respectively, while overt and occult CLD affected 2.85% and 4.61% of the population. The epidemiology of patients with overt and occult cirrhosis was similar but significantly different from that of the controls. Among subjects aged 60-70 years, working disability was twofold higher in those with occult cirrhosis compared to those with overt cirrhosis. Occult CLD and cirrhosis had higher prevalence rates than diagnosed cases in the general population. Electronic medical record data may serve as a valuable tool for CLD identification, potentially reducing cirrhosis development and clinical decompensation. This, in turn, may lead to a decrease in the economic impact on the healthcare system.
Collapse
Affiliation(s)
- Silvia Cagnin
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), Padova Teaching Hospital, Padua, Italy
| | - Andrea Martini
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), Padova Teaching Hospital, Padua, Italy
| | - Daniele Donato
- Medical Head Office, Padova Teaching Hospital, Padua, Italy
| | - Paolo Angeli
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), Padova Teaching Hospital, Padua, Italy
| | - Patrizia Pontisso
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), Padova Teaching Hospital, Padua, Italy.
| |
Collapse
|
2
|
Martini A, Pontisso P. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis-More evidence needed. Authors' reply. Aliment Pharmacol Ther 2024; 59:913-914. [PMID: 38462679 DOI: 10.1111/apt.17916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
LINKED CONTENTThis article is linked to Martini et al papers. To view these articles, visit https://doi.org/10.1111/apt.17804 and https://doi.org/10.1111/apt.17901
Collapse
Affiliation(s)
- Andrea Martini
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Patrizia Pontisso
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| |
Collapse
|
3
|
Haase FT, Ortega E, Saddeler S, Schmidt FP, Cruz D, Scholten F, Rüscher M, Martini A, Jeon HS, Herzog A, Hejral U, Davis EM, Timoshenko J, Knop-Gericke A, Lunkenbein T, Schulz S, Bergmann A, Roldan Cuenya B. Role of Fe decoration on the oxygen evolving state of Co 3O 4 nanocatalysts. Energy Environ Sci 2024; 17:2046-2058. [PMID: 38449571 PMCID: PMC10913145 DOI: 10.1039/d3ee02809g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 01/29/2024] [Indexed: 03/08/2024]
Abstract
The production of green hydrogen through alkaline water electrolysis is the key technology for the future carbon-neutral industry. Nanocrystalline Co3O4 catalysts are highly promising electrocatalysts for the oxygen evolution reaction and their activity strongly benefits from Fe surface decoration. However, limited knowledge of decisive catalyst motifs at the atomic level during oxygen evolution prevents their knowledge-driven optimization. Here, we employ a variety of operando spectroscopic methods to unveil how Fe decoration increases the catalytic activity of Co3O4 nanocatalysts as well as steer the (near-surface) active state formation. Our study shows a link of the termination-dependent Fe decoration to the activity enhancement and a significantly stronger Co3O4 near-surface (structural) adaptation under the reaction conditions. The near-surface Fe- and Co-O species accumulate an oxidative charge and undergo a reversible bond contraction during the catalytic process. Moreover, our work demonstrates the importance of low coordination surface sites on the Co3O4 host to ensure an efficient Fe-induced activity enhancement, providing another puzzle piece to facilitate optimized catalyst design.
Collapse
Affiliation(s)
- Felix T Haase
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Eduardo Ortega
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Sascha Saddeler
- Institute for Inorganic Chemistry and Center for Nanointegration Duisburg-Essen [CENIDE], University of Duisburg-Essen Essen Germany
| | - Franz-Philipp Schmidt
- Department of Inorganic Chemistry, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Daniel Cruz
- Department of Inorganic Chemistry, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Fabian Scholten
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Martina Rüscher
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Andrea Martini
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Hyo Sang Jeon
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Antonia Herzog
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Uta Hejral
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Earl M Davis
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Janis Timoshenko
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Axel Knop-Gericke
- Department of Inorganic Chemistry, Fritz Haber Institute of the Max Planck Society Berlin Germany
- Max-Planck-Institut für Chemische Energiekonversion, Stiftstrasse 34-36 45470 Mülheim Germany
| | - Thomas Lunkenbein
- Department of Inorganic Chemistry, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Stephan Schulz
- Institute for Inorganic Chemistry and Center for Nanointegration Duisburg-Essen [CENIDE], University of Duisburg-Essen Essen Germany
| | - Arno Bergmann
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| | - Beatriz Roldan Cuenya
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society Berlin Germany
| |
Collapse
|
4
|
Villano G, Novo E, Turato C, Quarta S, Ruvoletto M, Biasiolo A, Protopapa F, Chinellato M, Martini A, Trevellin E, Granzotto M, Cannito S, Cendron L, De Siervi S, Guido M, Parola M, Vettor R, Pontisso P. The protease activated receptor 2 - CCAAT/enhancer-binding protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of non-alcoholic steatohepatitis. Mol Metab 2024; 81:101889. [PMID: 38307387 PMCID: PMC10864841 DOI: 10.1016/j.molmet.2024.101889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 01/11/2024] [Accepted: 01/26/2024] [Indexed: 02/04/2024] Open
Abstract
OBJECTIVE The serine protease inhibitor SerpinB3 has been described as critical mediator of liver fibrosis and it has been recently proposed as an additional hepatokine involved in NASH development and insulin resistance. Protease Activated Receptor 2 has been identified as a novel regulator of hepatic metabolism. A targeted therapeutic strategy for NASH has been investigated, using 1-Piperidine Propionic Acid (1-PPA), since this compound has been recently proposed as both Protease Activated Receptor 2 and SerpinB3 inhibitor. METHODS The effect of SerpinB3 on inflammation and fibrosis genes was assessed in human macrophage and stellate cell lines. Transgenic mice, either overexpressing SerpinB3 or carrying Serpinb3 deletion and their relative wild type strains, were used in experimental NASH models. Subgroups of SerpinB3 transgenic mice and their controls were also injected with 1-PPA to assess the efficacy of this compound in NASH inhibition. RESULTS 1-PPA did not present significant cell and organ toxicity and was able to inhibit SerpinB3 and PAR2 in a dose-dependent manner. This effect was associated to a parallel reduction of the synthesis of the molecules induced by endogenous SerpinB3 or by its paracrine effects both in vitro and in vivo, leading to inhibition of lipid accumulation, inflammation and fibrosis in experimental NASH. At mechanistic level, the antiprotease activity of SerpinB3 was found essential for PAR2 activation, determining upregulation of the CCAAT Enhancer Binding Protein beta (C/EBP-β), another pivotal regulator of metabolism, inflammation and fibrosis, which in turn determined SerpinB3 synthesis. CONCLUSIONS 1-PPA treatment was able to inhibit the PAR2 - C/EBP-β - SerpinB3 axis and to protect from NASH development and progression, supporting the potential use of a similar approach for a targeted therapy of NASH.
Collapse
Affiliation(s)
- Gianmarco Villano
- Dept. of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy
| | - Erica Novo
- Dept. of Clinical and Biological Sciences, University of Torino, Italy
| | | | | | | | | | | | | | | | | | | | - Stefania Cannito
- Dept. of Clinical and Biological Sciences, University of Torino, Italy
| | | | | | - Maria Guido
- Dept. of Medicine, University of Padova, Italy
| | - Maurizio Parola
- Dept. of Clinical and Biological Sciences, University of Torino, Italy
| | | | | |
Collapse
|
5
|
Martini A, Turato C, Cannito S, Quarta S, Biasiolo A, Ruvoletto M, Novo E, Marafatto F, Guerra P, Tonon M, Clemente N, Bocca C, Piano SS, Guido M, Gregori D, Parola M, Angeli P, Pontisso P. The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation. Aliment Pharmacol Ther 2024; 59:380-392. [PMID: 37990490 DOI: 10.1111/apt.17804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 03/24/2023] [Accepted: 10/28/2023] [Indexed: 11/23/2023]
Abstract
BACKGROUND SerpinB3 is a cysteine protease inhibitor involved in liver disease progression due to its proinflammatory and profibrogenic properties. The polymorphic variant SerpinB3-PD (SB3-PD), presents a substitution in its reactive centre loop, determining the gain of function. AIMS To disclose the clinical characteristics of a cohort of patients with cirrhosis in relation to the presence of SB3-PD and to assess the effect of this genetic variant on fibrogenic and inflammatory cytokines in vitro. METHODS We assessed SB3 polymorphism in 90 patients with cirrhosis, prospectively followed up in our referral centre. We used HepG2 and HuH-7 cells transfected to overexpress either wild-type SB3 (SB3-WT) or SB3-PD to assess their endogenous effect, while LX2 and THP-1 cells were treated with exogenous SB3-WT or SB3-PD proteins. RESULTS Patients carrying SB3-PD had more severe portal hypertension and higher MELD scores, than patients carrying SB3-WT. In multivariate analysis, SB3-PD was an independent predictor of cirrhosis complications. Patients with SB3-PD polymorphism presented with more severe liver fibrosis and inflammatory features. Hepatoma cells overexpressing SB3-PD showed higher TGF-β1 expression than controls. The addition of recombinant SB3-PD induced an up-regulation of TGF-β1 in LX2 cells and a more prominent inflammatory profile in THP-1 cells, compared to the effect of SB3-WT protein. CONCLUSIONS The polymorphic variant SB3-PD is highly effective in determining activation of TGF-β1 and inflammation in vitro. Patients with cirrhosis who carry SB3-PD polymorphism may be more prone to develop severe liver disease progression. However, further validation studies are warranted to support the in vivo relevance of this polymorphism.
Collapse
Affiliation(s)
- Andrea Martini
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Cristian Turato
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Stefania Cannito
- Unit of Experimental Medicine and Clinical Pathology, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - Santina Quarta
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Alessandra Biasiolo
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Mariagrazia Ruvoletto
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Erica Novo
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Filippo Marafatto
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Pietro Guerra
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Marta Tonon
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Nausicaa Clemente
- Department of Health Science, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale, Novara, Italy
| | - Claudia Bocca
- Unit of Experimental Medicine and Clinical Pathology, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - Salvatore Silvio Piano
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Maria Guido
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Dario Gregori
- Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Maurizio Parola
- Unit of Experimental Medicine and Clinical Pathology, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - Paolo Angeli
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Patrizia Pontisso
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| |
Collapse
|
6
|
Martini A, Prasai K, Zemla TJ, Ahmed FY, Elnagar MB, Giama NH, Guzzardo V, Biasiolo A, Fassan M, Yin J, Pontisso P, Roberts LR. SerpinB3/4 Expression Is Associated with Poor Prognosis in Patients with Cholangiocarcinoma. Cancers (Basel) 2024; 16:225. [PMID: 38201652 PMCID: PMC10778206 DOI: 10.3390/cancers16010225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 12/30/2023] [Accepted: 01/01/2024] [Indexed: 01/12/2024] Open
Abstract
Cholangiocarcinoma (CCA), the second most common primary liver tumor, is associated with a dismal outcome, and useful prognostic markers are not currently available in clinical practice. SerpinB3, a serine protease inhibitor, was recently found to play a relevant role in malignant transformation in different cancers. The aim of the present study was to determine the expression of SerpinB3/4 in tissue and serum samples of patients with CCA in relation to clinical outcomes. SerpinB3/4 was assessed in the tissue microarrays (TMAs) of 123 surgically resected CCAs. ELISA assays were carried out in 188 patients with CCA to detect the free and IgM-linked forms of SerpinB3/4. Overall survival was analyzed in relation to SerpinB3/4 expression, and Cox models were used to identify the variables associated with survival. High levels of SerpinB3/4 (TMA score 2+/3+) were detected in 15 tumors (12.2%), characterized by a more advanced TNM stage (III/IV: 64.3% vs. 31.3%; p = 0.031) and lower overall patient survival, independently of CCA subclass (intrahepatic CCA: median 1.1 (0.8-Not Estimable, NE) vs. 2.4 (1.8-3.4) years; p = 0.0007; extrahepatic CCA: median 0.8 (0.2-NE) vs. 2.2 (1.5-5.4) years; p = 0.011). Vascular invasion (p = 0.027) and SerpinB3/4 scores (p = 0.0016) were independently associated with mortality in multivariate analysis. Patients who had detectable free or IgM-linked SerpinB3/4 in their serum showed poorer survival (1 vs. 2.4 years, p = 0.015, for free SerpinB3/4, and 1 vs. 2.6 years, p = 0.0026, for SerpinB3/4-IgM). In conclusion, high levels of SerpinB3/4 in tissue and serum in CCA are associated with poor outcomes after surgery, regardless of tumor subclass.
Collapse
Affiliation(s)
- Andrea Martini
- Department of Medicine, University of Padua, via Giustiniani 2, 35128 Padua, Italy; (A.M.); (V.G.); (A.B.); (M.F.)
| | - Kritika Prasai
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (K.P.); (F.Y.A.); (M.B.E.); (N.H.G.); (L.R.R.)
| | - Tyler J. Zemla
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (T.J.Z.); (J.Y.)
| | - Fowsiyo Y. Ahmed
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (K.P.); (F.Y.A.); (M.B.E.); (N.H.G.); (L.R.R.)
| | - Mamoun B. Elnagar
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (K.P.); (F.Y.A.); (M.B.E.); (N.H.G.); (L.R.R.)
| | - Nasra H. Giama
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (K.P.); (F.Y.A.); (M.B.E.); (N.H.G.); (L.R.R.)
| | - Vincenza Guzzardo
- Department of Medicine, University of Padua, via Giustiniani 2, 35128 Padua, Italy; (A.M.); (V.G.); (A.B.); (M.F.)
| | - Alessandra Biasiolo
- Department of Medicine, University of Padua, via Giustiniani 2, 35128 Padua, Italy; (A.M.); (V.G.); (A.B.); (M.F.)
| | - Matteo Fassan
- Department of Medicine, University of Padua, via Giustiniani 2, 35128 Padua, Italy; (A.M.); (V.G.); (A.B.); (M.F.)
- Veneto Institute of Oncology, (IOV-IRCCS), via Gattamelata 64, 35128 Padua, Italy
| | - Jun Yin
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (T.J.Z.); (J.Y.)
| | - Patrizia Pontisso
- Department of Medicine, University of Padua, via Giustiniani 2, 35128 Padua, Italy; (A.M.); (V.G.); (A.B.); (M.F.)
- European Reference Network—ERN RARE-LIVER, 72076 Tübingen, Germany
| | - Lewis R. Roberts
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA; (K.P.); (F.Y.A.); (M.B.E.); (N.H.G.); (L.R.R.)
| |
Collapse
|
7
|
Hursán D, Timoshenko J, Ortega E, Jeon HS, Rüscher M, Herzog A, Rettenmaier C, Chee SW, Martini A, Koshy D, Roldán Cuenya B. Reversible Structural Evolution of Metal-Nitrogen-Doped Carbon Catalysts During CO 2 Electroreduction: An Operando X-ray Absorption Spectroscopy Study. Adv Mater 2024; 36:e2307809. [PMID: 37994692 DOI: 10.1002/adma.202307809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 11/09/2023] [Indexed: 11/24/2023]
Abstract
Electrochemical CO2 reduction (CO2 RR) is a rising technology, aiming to reduce the energy sector dependence on fossil fuels and to produce carbon-neutral raw materials. Metal-nitrogen-doped carbons (M-N-C) are emerging, cost-effective catalysts for this reaction; however, their long-term stability is a major issue. To overcome this, understanding their structural evolution is crucial, requiring systematic in-depth operando studies. Here a series of M-N-C catalysts (M = Fe, Sn, Cu, Co, Ni, Zn) is investigated using operando X-ray absorption spectroscopy. It is found that the Fe-N-C and Sn-N-C are prone to oxide clusters formation even before CO2 RR. In contrast, the respective metal cations are singly dispersed in the as-prepared Cu-N-C, Co-N-C, Ni-N-C, and (Zn)-N-C. During CO2 RR, metallic clusters/nanoparticles reversibly formed in all catalysts, except for the Ni-N-C. This phenomenon, previously observed only in Cu-N-C, thus is ubiquitous in M-N-C catalysts. The competition between M-O and M-N interactions is an important factor determining the mobility of metal species in M-N-C. Specifically, the strong interaction between the Ni centers and the N-functional groups of the carbon support results in higher stability of the Ni single-sites, leading to the excellent performance of Ni-N-C in the CO2 to CO conversion, in comparison to other transition metals.
Collapse
Affiliation(s)
- Dorottya Hursán
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Janis Timoshenko
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Eduardo Ortega
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Hyo Sang Jeon
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Martina Rüscher
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Antonia Herzog
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Clara Rettenmaier
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - See Wee Chee
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Andrea Martini
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - David Koshy
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| | - Beatriz Roldán Cuenya
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195, Berlin, Germany
| |
Collapse
|
8
|
Saouli A, Touzani A, Martini A, Beauval JB, Dergamoun H, Ziouziou I, Deffar N, Ploussard G, Ouzzane A. Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 2023:10.1038/s41391-023-00752-5. [PMID: 37985863 DOI: 10.1038/s41391-023-00752-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Revised: 10/16/2023] [Accepted: 10/19/2023] [Indexed: 11/22/2023]
Abstract
CONTEXT There is a growing interest about the role of radical prostatectomy (RP) in local cancer control in oligometastatic prostate cancer (PCa). PURPOSE To evaluate the oncological and functional outcomes of RP in the management of oligometastatic PCa through a systematic review. METHODS A systematic review search was performed and the following bibliographic databases were accessed: PubMed, Scopus, Embase and the Cochrane central register of controlled trials were searched from January 2000 to November 2022. This was carried out by the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. RESULTS Based on the literature search of 384 articles, 11 (511 patients) met the inclusion criteria (mean age: 65.5 yr.). Positive surgical margins were 59%. Median follow-up ranged from 13 to 64 months. Clinical progression-free survival ranged from 56% at 3 years to 45% at 7 years. Specific and overall survival rates ranged from 60 to 80.5% and 78 to 80% at 5 years, respectively. Clavien ≥3 complications ranged from 0 to 21%. The urinary incontinence rate was 14.5%. CONCLUSIONS Similar to published studies, RP of oligometastatic PCa appears to be safe with acceptable morbidity in selected patients. The lack of a consensual definition, the low level of evidence and the bias of the comparative and retrospective studies available do not allow practical recommendations to be made. There is currently no place for metastatic surgery outside of participation in a clinical trial.
Collapse
Affiliation(s)
- A Saouli
- Department of urology, CHU Souss Massa, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco.
| | - A Touzani
- Casablanca Urology Center, Casablanca, Morocco
- Oasis Urology Center, Casablanca International Oncology Center, Casablanca, Morocco
- Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France
- IUCT-O, Toulouse, France
| | - A Martini
- Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France
- IUCT-O, Toulouse, France
- Department of Urology, M.D. Anderson Cancer Center, Houston, TX, USA
| | - J B Beauval
- Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France
- IUCT-O, Toulouse, France
| | - H Dergamoun
- Department of urology, CHU Souss Massa, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco
| | - I Ziouziou
- Department of urology, CHU Souss Massa, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco
| | - N Deffar
- Institut d'Urologie d'Auxerre, Polyclinique Sainte-Marguerite, Auxerre, France
- Institut de Cancérologie de Bourgogne, Dijon, France
| | - G Ploussard
- Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France
- IUCT-O, Toulouse, France
| | - A Ouzzane
- Casablanca Urology Center, Casablanca, Morocco
- Oasis Urology Center, Casablanca International Oncology Center, Casablanca, Morocco
- Institut d'Urologie d'Auxerre, Polyclinique Sainte-Marguerite, Auxerre, France
- Institut de Cancérologie de Bourgogne, Dijon, France
| |
Collapse
|
9
|
Cagnin S, Donghia R, Martini A, Pesole PL, Coletta S, Shahini E, Boninsegna G, Biasiolo A, Pontisso P, Giannelli G. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma. Int J Mol Sci 2023; 24:16485. [PMID: 38003675 PMCID: PMC10671761 DOI: 10.3390/ijms242216485] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 11/16/2023] [Accepted: 11/17/2023] [Indexed: 11/26/2023] Open
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) accounts for more than 75% of primary liver cancers, which are the second leading cause of cancer-related deaths. The GALAD (gender, age, AFP-L3, AFP, and des-carboxy-prothrombin) score is a diagnostic tool developed based on gender, age, alpha-fetoprotein, alpha-fetoprotein L3, and des-gamma-carboxy prothrombin, originally designed as a diagnostic tool for HCC in high-risk patients. METHODS We analyzed 212 patients with and without cirrhosis. The population study was divided into patients with liver cirrhosis without evidence of HCC at the time of serum sample collection for GALAD score determination and patients with liver cirrhosis and a confirmed diagnosis of HCC at the time of serum sample collection for GALAD score determination. Patients were followed up until death or liver transplantation. The association between variables and HCC mortality risk was performed, and the results were presented as hazard ratio (HR). The receiver operating characteristic (ROC) curve was used to assess the performance of the GALAD HCC diagnosis. The survival probability was explored using the non-parametric test, and the equality of survival amongst categories was assessed with the log-rank test. RESULTS Biomarkers were higher in the HCC group compared to cirrhosis. Kaplan-Meier survival probability analysis for individual GALAD categories revealed that a high GALAD level was associated with decreased survival during follow-up, and the difference between the curves was statistically significant (p = 0.01). CONCLUSIONS Our findings suggest that the GALAD score has promise as a prognostic tool, with implications for improving patient management and treatment strategies for HCC.
Collapse
Affiliation(s)
- Silvia Cagnin
- Department of Medicine, University of Padova, 35123 Padova, Italy; (S.C.); (A.M.); (G.B.); (A.B.); (P.P.)
| | - Rossella Donghia
- National Institute of Gastroenterology–IRCCS “Saverio de Bellis”, 70013 Castellana Grotte, Italy; (R.D.); (P.L.P.); (S.C.); (E.S.)
| | - Andrea Martini
- Department of Medicine, University of Padova, 35123 Padova, Italy; (S.C.); (A.M.); (G.B.); (A.B.); (P.P.)
| | - Pasqua Letizia Pesole
- National Institute of Gastroenterology–IRCCS “Saverio de Bellis”, 70013 Castellana Grotte, Italy; (R.D.); (P.L.P.); (S.C.); (E.S.)
| | - Sergio Coletta
- National Institute of Gastroenterology–IRCCS “Saverio de Bellis”, 70013 Castellana Grotte, Italy; (R.D.); (P.L.P.); (S.C.); (E.S.)
| | - Endrit Shahini
- National Institute of Gastroenterology–IRCCS “Saverio de Bellis”, 70013 Castellana Grotte, Italy; (R.D.); (P.L.P.); (S.C.); (E.S.)
| | - Giulia Boninsegna
- Department of Medicine, University of Padova, 35123 Padova, Italy; (S.C.); (A.M.); (G.B.); (A.B.); (P.P.)
| | - Alessandra Biasiolo
- Department of Medicine, University of Padova, 35123 Padova, Italy; (S.C.); (A.M.); (G.B.); (A.B.); (P.P.)
| | - Patrizia Pontisso
- Department of Medicine, University of Padova, 35123 Padova, Italy; (S.C.); (A.M.); (G.B.); (A.B.); (P.P.)
| | - Gianluigi Giannelli
- National Institute of Gastroenterology–IRCCS “Saverio de Bellis”, 70013 Castellana Grotte, Italy; (R.D.); (P.L.P.); (S.C.); (E.S.)
| |
Collapse
|
10
|
Adachi I, Adamczyk K, Aggarwal L, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Aversano M, Babu V, Bae H, Bahinipati S, Bambade P, Banerjee S, Barrett M, Baudot J, Bauer M, Baur A, Beaubien A, Becherer F, Becker J, Behera PK, Bennett JV, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhuyan B, Bianchi F, Bilka T, Biswas D, Bobrov A, Bodrov D, Bolz A, Bondar A, Borah J, Bozek A, Bračko M, Branchini P, Briere RA, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Cerasoli J, Chang MC, Chang P, Cheaib R, Cheema P, Chekelian V, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Choi SK, Choudhury S, Cochran J, Corona L, Cremaldi LM, Das S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dubey S, Dujany G, Ecker P, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finck C, Finocchiaro G, Fodor A, Forti F, Frey A, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Garg R, Garmash A, Gaudino G, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Ghosh D, Ghumaryan H, Giakoustidis G, Giordano R, Giri A, Gobbo B, Godang R, Gogota O, Goldenzweig P, Gradl W, Granderath S, Graziani E, Greenwald D, Gruberová Z, Gu T, Guan Y, Gudkova K, Halder S, Han Y, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Hedges MT, Heidelbach A, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hoek M, Hohmann M, Horak P, Hsu CL, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jang EJ, Ji QP, Jia S, Jin Y, Johnson A, Junkerkalefeld H, Kaliyar AB, Kandra J, Kang KH, Karyan G, Kawasaki T, Keil F, Ketter C, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumara K, Kunigo T, Kuzmin A, Kwon YJ, Lacaprara S, Lai YT, Lam T, Lanceri L, Lange JS, Laurenza M, Leboucher R, Le Diberder FR, Leitl P, Levit D, Lewis PM, Li C, Li LK, Li Y, Libby J, Liu QY, Liu ZQ, Liventsev D, Longo S, Lueck T, Luo T, Lyu C, Ma Y, Maggiora M, Maharana SP, Maiti R, Maity S, Mancinelli G, Manfredi R, Manoni E, Manthei AC, Mantovano M, Marcantonio D, Marcello S, Marinas C, Martel L, Martellini C, Martini A, Martinov T, Massaccesi L, Masuda M, Matsuda T, Matvienko D, Maurya SK, McKenna JA, Mehta R, Meier F, Merola M, Metzner F, Milesi M, Miller C, Mirra M, Miyabayashi K, Mohanty GB, Molina-Gonzalez N, Mondal S, Moneta S, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakazawa Y, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nazaryan G, Nisar NK, Nishida S, Ogawa S, Ono H, Oskin P, Otani F, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Parham K, Park SH, Paschen B, Passeri A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piccolo M, Piilonen LE, Podesta-Lerma PLM, Podobnik T, Pokharel S, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raeuber G, Raiz S, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Robertson SH, Roehrken M, Roney JM, Rostomyan A, Rout N, Russo G, Sahoo D, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schmitt C, Schnepf M, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shan W, Sharma C, Shen CP, Shi XD, Shillington T, Shiu JG, Shtol D, Shwartz B, Sibidanov A, Simon F, Singh JB, Skorupa J, Sobie RJ, Sobotzik M, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stavroulakis P, Stefkova S, Stottler ZS, Stroili R, Strube J, Sumihama M, Sumisawa K, Sutcliffe W, Svidras H, Takahashi M, Takizawa M, Tamponi U, Tanida K, Tenchini F, Thaller A, Tittel O, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Tsaklidis I, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Veronesi M, Vismaya VS, Vitale L, Vobbilisetti V, Volpe R, Wach B, Waheed E, Wakai M, Wallner S, Wang E, Wang MZ, Wang Z, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Yin JH, Yoshihara K, Yuan CZ, Zani L, Zhang Y, Zhilich V, Zhou JS, Zhou QD, Zhukova VI, Žlebčík R. Tests of Light-Lepton Universality in Angular Asymmetries of B^{0}→D^{*-}ℓν Decays. Phys Rev Lett 2023; 131:181801. [PMID: 37977641 DOI: 10.1103/physrevlett.131.181801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Accepted: 09/29/2023] [Indexed: 11/19/2023]
Abstract
We present the first comprehensive tests of the universality of the light leptons in the angular distributions of semileptonic B^{0}-meson decays to charged spin-1 charmed mesons. We measure five angular-asymmetry observables as functions of the decay recoil that are sensitive to lepton-universality-violating contributions. We use events where one neutral B is fully reconstructed in ϒ(4S)→BB[over ¯] decays in data corresponding to 189 fb^{-1} integrated luminosity from electron-positron collisions collected with the Belle II detector. We find no significant deviation from the standard model expectations.
Collapse
|
11
|
Adachi I, Aggarwal L, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Aversano M, Babu V, Bae H, Bahinipati S, Bambade P, Banerjee S, Barrett M, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Behera PK, Bennett JV, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhuyan B, Bianchi F, Bilka T, Biswas D, Bodrov D, Bondar A, Bozek A, Bračko M, Branchini P, Briere RA, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Cerasoli J, Chang MC, Chang P, Cheema P, Chekelian V, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Choi SK, Choudhury S, Cochran J, Corona L, Das S, Dattola F, De La Motte SA, de Marino G, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dreyer S, Dubey S, Dujany G, Ecker P, Epifanov D, Feichtinger P, Ferlewicz D, Finck C, Finocchiaro G, Fodor A, Forti F, Frey A, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Garmash A, Gaudino G, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Ghosh D, Ghumaryan H, Giakoustidis G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Gogota O, Goldenzweig P, Gradl W, Graziani E, Greenwald D, Gruberová Z, Gu T, Guan Y, Gudkova K, Han Y, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hershenhorn A, Higuchi T, Hill EC, Hoek M, Hohmann M, Hsu CL, Humair T, Iijima T, Inami K, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Junkerkalefeld H, Kaliyar AB, Kandra J, Karyan G, Kawasaki T, Keil F, Ketter C, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Korobov A, Korpar S, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumar R, Kumara K, Kuzmin A, Kwon YJ, Lacaprara S, Lai YT, Lam T, Lange JS, Laurenza M, Leboucher R, Le Diberder FR, Leitl P, Levit D, Lewis PM, Li LK, Libby J, Liu QY, Liu ZQ, Liventsev D, Longo S, Lueck T, Lyu C, Ma Y, Maggiora M, Maharana SP, Maiti R, Maity S, Manfredi R, Manoni E, Mantovano M, Marcantonio D, Marcello S, Marinas C, Martellini C, Martini A, Martinov T, Massaccesi L, Masuda M, Matsuda T, Matsuoka K, Matvienko D, Maurya SK, McKenna JA, Mehta R, Meier F, Merola M, Metzner F, Milesi M, Miller C, Mirra M, Miyabayashi K, Mohanty GB, Molina-Gonzalez N, Mondal S, Moneta S, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakazawa Y, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nazaryan G, Nisar NK, Nishida S, Ono H, Otani F, Oxford ER, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Passeri A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piccolo M, Piilonen LE, Podobnik T, Pokharel S, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rados P, Raeuber G, Raiz S, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Roney JM, Rostomyan A, Rout N, Russo G, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schmitt C, Schwanda C, Schwartz AJ, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shan W, Shi XD, Shillington T, Shiu JG, Shtol D, Sibidanov A, Simon F, Sobie RJ, Sobotzik M, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stavroulakis P, Stottler ZS, Stroili R, Sumihama M, Svidras H, Takahashi M, Takizawa M, Tamponi U, Tanida K, Tenchini F, Tittel O, Tonelli D, Torassa E, Trabelsi K, Tsaklidis I, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varvell KE, Veronesi M, Vismaya VS, Vitale L, Volpe R, Wach B, Wallner S, Wang E, Wang MZ, Wang XL, Wang Z, Warburton A, Watanabe M, Wessel C, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Yoshihara K, Yuan CZ, Yusa Y, Zhang Y, Zhilich V, Zhou JS, Zhou QD, Zhukova VI, Žlebčík R. Precise Measurement of the D_{s}^{+} Lifetime at Belle II. Phys Rev Lett 2023; 131:171803. [PMID: 37955504 DOI: 10.1103/physrevlett.131.171803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 09/14/2023] [Indexed: 11/14/2023]
Abstract
We measure the lifetime of the D_{s}^{+} meson using a data sample of 207 fb^{-1} collected by the Belle II experiment running at the SuperKEKB asymmetric-energy e^{+}e^{-} collider. The lifetime is determined by fitting the decay-time distribution of a sample of 116×10^{3} D_{s}^{+}→ϕπ^{+} decays. Our result is τ_{D_{s}^{+}}=(499.5±1.7±0.9) fs, where the first uncertainty is statistical and the second is systematic. This result is significantly more precise than previous measurements.
Collapse
|
12
|
Vimercati L, Cavone D, Negrisolo O, Pentimone F, De Maria L, Caputi A, Sponselli S, Delvecchio G, Cafaro F, Chellini E, Binazzi A, Di Marzio D, Mensi C, Consonni D, Migliore E, Brentisci C, Martini A, Negro C, D'Agostin F, Grappasonni I, Pascucci C, Benfatto L, Malacarne D, Casotto V, Comiati V, Storchi C, Mangone L, Murano S, Rossin L, Tallarigo F, Vitale F, Verardo M, Eccher S, Madeo G, Staniscia T, Carrozza F, Cozzi I, Romeo E, Pelullo P, Labianca M, Melis M, Cascone G, Ferri GM, Serio G. Mesothelioma Risk Among Maritime Workers According to Job Title: Data From the Italian Mesothelioma Register (ReNaM). Med Lav 2023; 114:e2023038. [PMID: 37878258 PMCID: PMC10627101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 07/12/2023] [Indexed: 10/26/2023]
Abstract
The study describes the 466 cases of malignant mesotheliomas (MM) collected by the National Mesothelioma Register (ReNaM) in Italy in the period 1993-2018 relating to subjects with exclusive asbestos exposure in merchant or military navy. The cases among maritime workers represent 1.8% of the total cases with defined exposure registred in the ReNaM, of which 212 cases (45.4%) among merchant maritime workers and 254 cases (54.5%) among navy. The distribution by site of mesothelioma showed 453 (97.2%) MM cases of the pleura, 11 (2.3%) of the peritoneum and 2 (0.4%) of the tunica vaginalis of the testis. With regard to occupational exposure, it was classified as certain in 318 (68.2%) cases, probable in 69 (14.8%) cases and possible in 79 (16.9%) cases. Among the 23 classified jobs, the highest percentages of certain exposures are among naval engineers, motor mechanics, machine captains and sailors. Machine crew accounted for 49.3% of the cases, deck crew for 27.6%. All cases began exposure on board between 1926 and 1988. Seamen were exposed to asbestos while at sea by virtue of living onboard ships and from continual release of asbestos fibers due to the motion of a vessel. Epidemiological surveillance through the ReNaM has allowed us to verify among cases in the maritime, navy and merchant marine sectors, that in the past, subjects were exposed regardless of the ship's department where have provided service therefore all these cases must be considered as occupational diseases.
Collapse
Affiliation(s)
- Luigi Vimercati
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Domenica Cavone
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Omero Negrisolo
- Environmental Prevention Technician former Judicial Police Officer Padua .
| | - Floriana Pentimone
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Luigi De Maria
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Antonio Caputi
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Stefania Sponselli
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Giuseppe Delvecchio
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Francesco Cafaro
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | | | - Alessandra Binazzi
- Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Italian Workers' Compensation Authority (INAIL), 00143 Rome, Italy.
| | - Davide Di Marzio
- Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Italian Workers' Compensation Authority (INAIL), 00143 Rome, Italy.
| | - Carolina Mensi
- Epidemiology Unit, Regional Operating Center of Lombardia (COR Lombardia), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.
| | - Dario Consonni
- Epidemiology Unit, Regional Operating Center of Lombardia (COR Lombardia), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.
| | - Enrica Migliore
- Unit of Cancer Epidemiology, Regional Operating Center of Piemonte (COR Piemonte), University of Torino and CPO-Piemonte, 10126 Torino, Italy.
| | - Carol Brentisci
- Unit of Cancer Epidemiology, Regional Operating Center of Piemonte (COR Piemonte), University of Torino and CPO-Piemonte, 10126 Torino, Italy.
| | - Andrea Martini
- Prevention and Clinical Network, Institute for Cancer Research, Regional Operating Center of Toscana (COR Toscana), 50139 Firenze, Italy.
| | - Corrado Negro
- Clinical Unit of Occupational Medicine, Regional Operating Center of Friuli-Venezia Giulia (COR Friu-li-Venezia Giulia), University of Trieste-Trieste General Hospitals, 34123 Trieste, Italy.
| | - Flavia D'Agostin
- Clinical Unit of Occupational Medicine, Regional Operating Center of Friuli-Venezia Giulia (COR Friu-li-Venezia Giulia), University of Trieste-Trieste General Hospitals, 34123 Trieste, Italy.
| | - Iolanda Grappasonni
- Regional Operating Center of Marche (COR Marche), School of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, Italy.
| | - Cristiana Pascucci
- Regional Operating Center of Marche (COR Marche), School of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, Italy.
| | - Lucia Benfatto
- Regional Operating Center of Liguria (COR Liguria Regional Operating Center of Liguria (COR Liguria), Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
| | - Davide Malacarne
- Regional Operating Center of Liguria (COR Liguria Regional Operating Center of Liguria (COR Liguria), Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
| | - Veronica Casotto
- Azienda Zero, Epidemiological Department, Regional Operating Center of Veneto (COR Veneto), Veneto Region, 35131 Padova, Italy.
| | - Vera Comiati
- Azienda Zero, Epidemiological Department, Regional Operating Center of Veneto (COR Veneto), Veneto Region, 35131 Padova, Italy.
| | - Cinzia Storchi
- Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
| | - Lucia Mangone
- Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy .
| | - Stefano Murano
- Occupational Medicine Unit, Alto Adige Health Authority, Regional Operating Center of Autonomous Province of Bolzano (COR A.P. of Bolzano), 39100 Bolzano, Italy.
| | - Lucia Rossin
- Occupational Medicine Unit, Alto Adige Health Authority, Regional Operating Center of Autonomous Province of Bolzano (COR A.P. of Bolzano), 39100 Bolzano, Italy.
| | - Federico Tallarigo
- Public Health Unit, Regional Operating Center of Calabria (COR Calabria), 88900 Crotone, Italy.
| | - Filomena Vitale
- Public Health Unit, Regional Operating Center of Calabria (COR Calabria), 88900 Crotone, Italy.
| | - Marina Verardo
- Valle d'Aosta Health Local Unit, Regional Operating Center of Valle d'Aosta (COR Valle d'Aosta), 11100 Aosta, Italy.
| | - Silvia Eccher
- Hygiene and Occupational Medicine, Provincial Unit of Health, Regional Operating Center o Autono-mous Province of Trento (COR A.P. of Trento), 38100 Trento, Italy.
| | - Gabriella Madeo
- Center of Umbria (COR Umbria), Servizio Prevenzione, Sanità Veterinaria e Sicurezza Alimen-tare-Regione Umbria, 06126 Perugia, Italy.
| | - Tommaso Staniscia
- COR Abruzzo, Abruzzo Regional Health Agency (ASR), Pescara, Italy; 65121 Pescara, Italy.
| | - Francesco Carrozza
- Oncology Unit, Cardarelli Hospital, Regional Operating Center of Molise (COR Molise), 86100 Campo-basso, Italy.
| | - Ilaria Cozzi
- Regional Operating Center of Lazio (COR Lazio), Department of Epidemiology, Epidemiology Lazio Re-gional Health Service, ASL Roma 1, 00147 Roma, Italy.
| | - Elisa Romeo
- Regional Operating Center of Lazio (COR Lazio), Department of Epidemiology, Epidemiology Lazio Re-gional Health Service, ASL Roma 1, 00147 Roma, Italy.
| | - Paola Pelullo
- Department of Experimental Medicine, "Luigi Vanvitelli" University, Regional Operating Center of Campania (COR Campania), 80138 Napoli, Italy.
| | - Michele Labianca
- Epidemiologic Regional Center, Regional Operating Center of Basilicata (COR Basilicata), 85100 Poten-za, Italy.
| | - Massimo Melis
- Regional Epidemiological Center, Regional Operating Center of Sardegna (COR Sardegna), 09125 Ca-gliari, Italy.
| | - Giuseppe Cascone
- Regional Operating Center of Sicilia (COR Sicilia), 97100 Ragusa, Italy; ASP Ragusa Dipartimento di Prevenzione Medica .
| | | | - Gabriella Serio
- Department of Emergency and Organ Transplantation (DETO), Pathological Anatomy Section, Univer-sity of Bari Aldo Moro, Bari, Italy.
| |
Collapse
|
13
|
Adachi I, Adamczyk K, Aggarwal L, Ahmed H, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Aversano M, Babu V, Bae H, Bahinipati S, Bambade P, Banerjee S, Bansal S, Barrett M, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhardwaj V, Bhuyan B, Bianchi F, Bilka T, Bilokin S, Biswas D, Bobrov A, Bodrov D, Bolz A, Borah J, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Cerasoli J, Chang MC, Chang P, Cheaib R, Cheema P, Chekelian V, Chen YQ, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Cochran J, Corona L, Cremaldi LM, Cunliffe S, Czank T, Das S, Dattola F, De La Cruz-Burelo E, De La Motte SA, de Marino G, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dubey S, Dujany G, Ecker P, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finck C, Finocchiaro G, Fodor A, Forti F, Frey A, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Garmash A, Gaudino G, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Ghosh D, Ghumaryan H, Giakoustidis G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Gogota O, Goldenzweig P, Gradl W, Grammatico T, Granderath S, Graziani E, Greenwald D, Gruberová Z, Gu T, Guan Y, Gudkova K, Guilliams J, Halder S, Han Y, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hirata H, Hoek M, Hohmann M, Hsu CL, Humair T, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Johnson A, Joo KK, Junkerkalefeld H, Kakuno H, Kaleta M, Kalita D, Kaliyar AB, Kandra J, Kang KH, Kang S, Karl R, Karyan G, Kawasaki T, Keil F, Ketter C, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumar R, Kumara K, Kunigo T, Kuzmin A, Kwon YJ, Lacaprara S, Lai YT, Lam T, Lanceri L, Lange JS, Laurenza M, Lautenbach K, Leboucher R, Le Diberder FR, Leitl P, Levit D, Lewis PM, Li C, Li LK, Li YB, Libby J, Lieret K, Liu QY, Liu ZQ, Liventsev D, Longo S, Lozar A, Lueck T, Lyu C, Ma Y, Maggiora M, Maharana SP, Maiti R, Maity S, Manfredi R, Manoni E, Manthei AC, Mantovano M, Marcantonio D, Marcello S, Marinas C, Martel L, Martellini C, Martini A, Martinov T, Massaccesi L, Masuda M, Matsuda T, Matsuoka K, Matvienko D, Maurya SK, McKenna JA, Mehta R, Merola M, Metzner F, Milesi M, Miller C, Mirra M, Miyabayashi K, Miyake H, Mizuk R, Mohanty GB, Molina-Gonzalez N, Mondal S, Moneta S, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakamura KR, Nakao M, Nakayama H, Nakazawa H, Nakazawa Y, Narimani Charan A, Naruki M, Narwal D, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nazaryan G, Niebuhr C, Nisar NK, Nishida S, Ogawa S, Ono H, Onuki Y, Oskin P, Otani F, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Parham K, Park J, Park SH, Paschen B, Passeri A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piccolo M, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raeuber G, Raiz S, Ramirez Morales A, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Rizzuto LB, Robertson SH, Rodríguez Pérez D, Roehrken M, Roney JM, Rostomyan A, Rout N, Russo G, Sahoo D, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schnepf M, Schueler J, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shan W, Sharma C, Shen CP, Shi XD, Shillington T, Shiu JG, Shtol D, Shwartz B, Sibidanov A, Simon F, Singh JB, Skorupa J, Sobie RJ, Sobotzik M, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stavroulakis P, Stefkova S, Stottler ZS, Stroili R, Strube J, Sue Y, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Takahashi M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Tenchini F, Thaller A, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Tsaklidis I, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vismaya VS, Vitale L, Vobbilisetti V, Volpe R, Vossen A, Wach B, Wakai M, Wakeling HM, Wallner S, Wang E, Wang MZ, Wang XL, Wang Z, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yelton J, Yin JH, Yook YM, Yoshihara K, Yuan CZ, Yusa Y, Zani L, Zhai Y, Zhang Y, Zhilich V, Zhou JS, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Search for a τ^{+}τ^{-} Resonance in e^{+}e^{-}→μ^{+}μ^{-}τ^{+}τ^{-} Events with the Belle II Experiment. Phys Rev Lett 2023; 131:121802. [PMID: 37802942 DOI: 10.1103/physrevlett.131.121802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Accepted: 08/08/2023] [Indexed: 10/08/2023]
Abstract
We report the first search for a nonstandard-model resonance decaying into τ pairs in e^{+}e^{-}→μ^{+}μ^{-}τ^{+}τ^{-} events in the 3.6-10 GeV/c^{2} mass range. We use a 62.8 fb^{-1} sample of e^{+}e^{-} collisions collected at a center-of-mass energy of 10.58 GeV by the Belle II experiment at the SuperKEKB collider. The analysis probes three different models predicting a spin-1 particle coupling only to the heavier lepton families, a Higgs-like spin-0 particle that couples preferentially to charged leptons (leptophilic scalar), and an axionlike particle, respectively. We observe no evidence for a signal and set exclusion limits at 90% confidence level on the product of cross section and branching fraction into τ pairs, ranging from 0.7 to 24 fb, and on the couplings of these processes. We obtain world-leading constraints on the couplings for the leptophilic scalar model for masses above 6.5 GeV/c^{2} and for the axionlike particle model over the entire mass range.
Collapse
|
14
|
Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, Pera G, Grgurevic I, Caballeria L, Piano S, van Kleef L, Reichert M, Roulot D, Pericàs JM, Schattenberg JM, Tsochatztis EA, Guha IN, Garcia-Retortillo M, Hernández R, Hoyo J, Fuentes M, Expósito C, Martínez A, Such P, Madir A, Detlefsen S, Tonon M, Martini A, Ma AT, Pich J, Bonfill E, Juan M, Soria A, Carol M, Gratacós-Ginès J, Morillas RM, Toran P, Navarrete JM, Torrejón A, Fournier C, Llorca A, Arslanow A, de Koning HJ, Cucchietti F, Manns M, Newsome PN, Hernáez R, Allen A, Angeli P, de Knegt RJ, Karlsen TH, Galle P, Wong VWS, Fabrellas N, Castera L, Krag A, Lammert F, Kamath PS, Ginès P. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 2023; 402:988-996. [PMID: 37572680 DOI: 10.1016/s0140-6736(23)01174-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 04/04/2023] [Accepted: 06/05/2023] [Indexed: 08/14/2023]
Abstract
BACKGROUND Liver cirrhosis is a major cause of death worldwide. Cirrhosis develops after a long asymptomatic period of fibrosis progression, with the diagnosis frequently occurring late, when major complications or cancer develop. Few reliable tools exist for timely identification of individuals at risk of cirrhosis to allow for early intervention. We aimed to develop a novel score to identify individuals at risk for future liver-related outcomes. METHODS We derived the LiverRisk score from an international prospective cohort of individuals from six countries without known liver disease from the general population, who underwent liver fibrosis assessment by transient elastography. The score included age, sex, and six standard laboratory variables. We created four groups: minimal risk, low risk, medium risk, and high risk according to selected cutoff values of the LiverRisk score (6, 10, and 15). The model's discriminatory accuracy and calibration were externally validated in two prospective cohorts from the general population. Moreover, we ascertained the prognostic value of the score in the prediction of liver-related outcomes in participants without known liver disease with median follow-up of 12 years (UK Biobank cohort). FINDINGS We included 14 726 participants: 6357 (43·2%) in the derivation cohort, 4370 (29·7%) in the first external validation cohort, and 3999 (27·2%) in the second external validation cohort. The score accurately predicted liver stiffness in the development and external validation cohorts, and was superior to conventional serum biomarkers of fibrosis, as measured by area under the receiver-operating characteristics curve (AUC; 0·83 [95% CI [0·78-0·89]) versus the fibrosis-4 index (FIB-4; 0·68 [0·61-0·75] at 10 kPa). The score was effective in identifying individuals at risk of liver-related mortality, liver-related hospitalisation, and liver cancer, thereby allowing stratification to different risk groups for liver-related outcomes. The hazard ratio for liver-related mortality in the high-risk group was 471 (95% CI 347-641) compared with the minimal risk group, and the overall AUC of the score in predicting 10-year liver-related mortality was 0·90 (0·88-0·91) versus 0.84 (0·82-0·86) for FIB-4. INTERPRETATION The LiverRisk score, based on simple parameters, predicted liver fibrosis and future development of liver-related outcomes in the general population. The score might allow for stratification of individuals according to liver risk and thus guide preventive care. FUNDING European Commission under the H20/20 programme; Fondo de Investigación Sanitaria de Salud; Instituto de Salud Carlos III; Spanish Ministry of Economy, Industry, and Competitiveness; the European Regional Development Fund; and the German Ministry of Education and Research (BMBF).
Collapse
Affiliation(s)
- Miquel Serra-Burriel
- Epidemiology, Statistics, and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - Adrià Juanola
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | | | - Maja Thiele
- Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, and Institute for Clinical Research, University of Southern Denmark Odense, Odense, Denmark
| | - Isabel Graupera
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Elisa Pose
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Guillem Pera
- Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Mataró, Barcelona, Spain
| | - Ivica Grgurevic
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia
| | - Llorenç Caballeria
- Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Metropolitana Nord, IDIAP Jordi Gol, ICS Institut Català de la Salut, Barcelona, Spain
| | - Salvatore Piano
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy
| | - Laurens van Kleef
- Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, Netherlands
| | - Mathias Reichert
- Department of Medicine II, Saarland University Medical Center, Homburg, Germany
| | - Dominique Roulot
- Unité d'Hépatologie, Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny, France
| | - Juan M Pericàs
- Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jörn M Schattenberg
- Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Emmanuel A Tsochatztis
- UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College of London, London, UK
| | - Indra Neil Guha
- NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
| | | | - Rosario Hernández
- Institut Catala de la Salut, BCN, Ambit d'Atencio Primaria, Barcelona, Spain
| | - Jordi Hoyo
- Institut Catala de la Salut, BCN, Ambit d'Atencio Primaria, Barcelona, Spain
| | - Matilde Fuentes
- Institut Catala de la Salut, BCN, Ambit d'Atencio Primaria, Barcelona, Spain
| | - Carmen Expósito
- Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Mataró, Barcelona, Spain
| | - Alba Martínez
- Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Mataró, Barcelona, Spain
| | - Patricia Such
- Health, Safety and Emergencies of SEAT, CUPRA and the Volkswagen Group Companies in Spain, Martorell, Spain
| | - Anita Madir
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia
| | - Sönke Detlefsen
- Department of Pathology, Odense University Hospital, and Institute for Clinical Research, University of Southern Denmark Odense, Odense, Denmark
| | - Marta Tonon
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy
| | - Andrea Martini
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy
| | - Ann T Ma
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Judith Pich
- Clinical Trial Unit, Hospital Clínic, Barcelona, Spain
| | - Eva Bonfill
- Clinical Trial Unit, Hospital Clínic, Barcelona, Spain
| | - Marta Juan
- Clinical Trial Unit, Hospital Clínic, Barcelona, Spain
| | - Anna Soria
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Marta Carol
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Jordi Gratacós-Ginès
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Rosa M Morillas
- Liver Unit, Hospital Germans Trias i Pujol, IGTP, Badalona, Spain
| | - Pere Toran
- Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Mataró, Barcelona, Spain
| | - J M Navarrete
- Health, Safety and Emergencies of SEAT, CUPRA and the Volkswagen Group Companies in Spain, Martorell, Spain
| | - Antoni Torrejón
- Health, Safety and Emergencies of SEAT, CUPRA and the Volkswagen Group Companies in Spain, Martorell, Spain
| | | | | | - Anita Arslanow
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain
| | - Harry J de Koning
- Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, Netherlands
| | | | - Michael Manns
- Health Sciences, Hannover Medical School MHH, Hannover, Germany
| | - Phillip N Newsome
- National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK
| | - Rubén Hernáez
- Division of Gastroenterology and Hepatology, Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA; Center for Innovations in Quality, Effectiveness and Safety, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA; Division of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Alina Allen
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
| | - Paolo Angeli
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy
| | - Robert J de Knegt
- Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, Netherlands
| | - Tom H Karlsen
- Section of Gastroenterology, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway
| | - Peter Galle
- Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Vincent Wai-Sun Wong
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Núria Fabrellas
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain
| | - Laurent Castera
- Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, Université de Paris, Paris, France
| | - Aleksander Krag
- Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, and Institute for Clinical Research, University of Southern Denmark Odense, Odense, Denmark
| | - Frank Lammert
- Department of Medicine II, Saarland University Medical Center, Homburg, Germany; Institute for Occupational Medicine and Public Health, Saarland University, Homburg, Germany; Hannover Medical School, Hannover, Germany
| | - Patrick S Kamath
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
| | - Pere Ginès
- Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain.
| |
Collapse
|
15
|
Martini A, Hursán D, Timoshenko J, Rüscher M, Haase F, Rettenmaier C, Ortega E, Etxebarria A, Roldan Cuenya B. Tracking the Evolution of Single-Atom Catalysts for the CO 2 Electrocatalytic Reduction Using Operando X-ray Absorption Spectroscopy and Machine Learning. J Am Chem Soc 2023; 145:17351-17366. [PMID: 37524049 PMCID: PMC10416299 DOI: 10.1021/jacs.3c04826] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Indexed: 08/02/2023]
Abstract
Transition metal-nitrogen-doped carbons (TMNCs) are a promising class of catalysts for the CO2 electrochemical reduction reaction. In particular, high CO2-to-CO conversion activities and selectivities were demonstrated for Ni-based TMNCs. Nonetheless, open questions remain about the nature, stability, and evolution of the Ni active sites during the reaction. In this work, we address this issue by combining operando X-ray absorption spectroscopy with advanced data analysis. In particular, we show that the combination of unsupervised and supervised machine learning approaches is able to decipher the X-ray absorption near edge structure (XANES) of the TMNCs, disentangling the contributions of different metal sites coexisting in the working TMNC catalyst. Moreover, quantitative structural information about the local environment of active species, including their interaction with adsorbates, has been obtained, shedding light on the complex dynamic mechanism of the CO2 electroreduction.
Collapse
Affiliation(s)
- Andrea Martini
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | | | - Janis Timoshenko
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | - Martina Rüscher
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | - Felix Haase
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | - Clara Rettenmaier
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | - Eduardo Ortega
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | - Ane Etxebarria
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| | - Beatriz Roldan Cuenya
- Department of Interface Science, Fritz-Haber Institute of the Max Planck Society, 14195 Berlin, Germany
| |
Collapse
|
16
|
Aggarwal L, Ahmed H, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Bae H, Bahinipati S, Bambade P, Banerjee S, Bansal S, Barrett M, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhardwaj V, Bhuyan B, Bianchi F, Bilka T, Bilokin S, Biswas D, Bodrov D, Borah J, Bozek A, Bračko M, Briere RA, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Cerasoli J, Chang MC, Cheaib R, Cheema P, Chekelian V, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cochran J, Corona L, Cunliffe S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dhamija R, Di Capua F, Dingfelder J, Doležal Z, Dong TV, Dorigo M, Dossett D, Dreyer S, Dubey S, Dujany G, Ecker P, Eliachevitch M, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finocchiaro G, Fodor A, Forti F, Frey A, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Gaudino G, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Gradl W, Grammatico T, Granderath S, Graziani E, Gruberová Z, Gu T, Gudkova K, Halder S, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hohmann M, Hsu CL, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jacobs WW, Jang EJ, Ji QP, Jia S, Jin Y, Junkerkalefeld H, Kaleta M, Kaliyar AB, Karyan G, Kawasaki T, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Kohani S, Kojima K, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Križan P, Krokovny P, Kumar J, Kumar R, Kumara K, Kuzmin A, Kwon YJ, Lacaprara S, Lange JS, Laurenza M, Leboucher R, Le Diberder FR, Levit D, Lewis PM, Li LK, Libby J, Liptak Z, Liu QY, Liu ZQ, Liventsev D, Longo S, Lueck T, Lyu C, Ma Y, Maggiora M, Maharana SP, Maiti R, Maity S, Manfredi R, Manoni E, Manthei AC, Mantovano M, Marinas C, Martel L, Martellini C, Martini A, Massaccesi L, Masuda M, Matsuoka K, Matvienko D, Maurya SK, McKenna JA, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mizuk R, Mohanty GB, Moneta S, Mrvar M, Mussa R, Nakamura I, Nakamura KR, Nakao M, Nakazawa Y, Narimani Charan A, Naruki M, Narwal D, Natochii A, Nayak L, Nazaryan G, Nisar NK, Nishida S, Ono H, Onuki Y, Oskin P, Pakhlov P, Pakhlova G, Paladino A, Panta A, Pardi S, Park H, Park J, Paschen B, Passeri A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raeuber G, Reif M, Reiter S, Ripp-Baudot I, Rizzo G, Rizzuto LB, Rocchetti P, Roney JM, Rostomyan A, Rout N, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Scavino B, Schwanda C, Seino Y, Selce A, Senyo K, Sevior ME, Sfienti C, Shan W, Sharma C, Shen CP, Shillington T, Shiu JG, Simon F, Singh JB, Skorupa J, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stroili R, Sue Y, Sumihama M, Sutcliffe W, Suzuki SY, Svidras H, Takizawa M, Tamponi U, Tanida K, Taniguchi N, Tenchini F, Tiwary R, Tonelli D, Torassa E, Trabelsi K, Tsaklidis I, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vismaya VS, Vitale L, Vossen A, Wallner S, Wang E, Wang MZ, Wang XL, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yin JH, Yook YM, Yoshihara K, Zhai Y, Zhang Y, Zhilich V, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Test of Light-Lepton Universality in the Rates of Inclusive Semileptonic B-Meson Decays at Belle II. Phys Rev Lett 2023; 131:051804. [PMID: 37595249 DOI: 10.1103/physrevlett.131.051804] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 05/03/2023] [Accepted: 05/11/2023] [Indexed: 08/20/2023]
Abstract
We present the first measurement of the ratio of branching fractions of inclusive semileptonic B-meson decays, R(X_{e/μ})=B(B→Xeν)/B(B→Xμν), a precision test of electron-muon universality, using data corresponding to 189 fb^{-1} from electron-positron collisions collected with the Belle II detector. In events where the partner B meson is fully reconstructed, we use fits to the lepton momentum spectra above 1.3 GeV/c to obtain R(X_{e/μ})=1.007±0.009(stat)±0.019(syst), which is the most precise lepton-universality test of its kind and agrees with the standard-model expectation.
Collapse
|
17
|
Zanatta E, Cocconcelli E, Castelli G, Giraudo C, Fraia AS, De Zorzi E, Gatto M, Ienna L, Treppo E, Malandrino D, Cereser L, Emmi G, Giannelli F, Bellani S, Martini A, Moccaldi B, Ghirardello A, Avouac J, Quartuccio L, Allanore Y, Doria A, Spagnolo P, Balestro E, Iaccarino L. Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort. RMD Open 2023; 9:e003121. [PMID: 37541742 PMCID: PMC10407351 DOI: 10.1136/rmdopen-2023-003121] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 07/17/2023] [Indexed: 08/06/2023] Open
Abstract
OBJECTIVES Patients with connective tissue diseases can develop interstitial lung disease (ILD), leading to a progressive fibrosing ILD (PF-ILD) phenotype in some cases. We aimed to investigate the occurrence of PF-ILD in idiopathic inflammatory myopathies (IIMs), and factors potentially predicting this phenotype. Secondary aims were to assess the radiological pattern and factors associated with IIMs-ILD. METHODS Patients with IIMs from our multicentric prospective cohort were retrospectively evaluated. Data were recorded at IIMs and ILD diagnosis, and during follow-up. Patients with ILD were classified according to the predominant high-resolution CT (HRCT) pattern: non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP) and organising pneumonia (OP). PF-ILD was defined according to the 2022 American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS) and Latin American Thoracic Society (ALAT) guidelines. Univariate and multivariate analyses were performed to identify factors associated to ILD and to PF-ILD. RESULTS Of 253 patients with IIMs, 125 (49%) had ILD: 99 (78%) at IIMs diagnosis and 26 (22%) during follow-up (21/26 within 5 years). Multivariate analysis identified anti-Jo-1, anti-MDA5, anti-Ro52, high score on manual muscle test, mechanic's hands and Raynaud's phenomenon as independently associated with ILD. The predominant HRCT pattern was NSIP (50% of patients), followed by UIP (28%) and OP (22%). At 1-year follow-up, PF-ILD occurred in 18% of IIMs-ILD. PF-ILD was predicted by anti-MDA5, heliotropic rash, xerostomia and xerophthalmia at univariate but not at multivariate analysis. CONCLUSION Patients with IIM should be carefully screened for ILD at IIMs diagnosis and yearly during follow-up. All patients with IIMs-ILD should be carefully monitored to capture ILD progression since a consistent proportion of them are expected to develop PF-ILD.
Collapse
Affiliation(s)
- Elisabetta Zanatta
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| | - Elisabetta Cocconcelli
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, Padova, Italy
| | - Gioele Castelli
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, Padova, Italy
| | - Chiara Giraudo
- Unit of Advanced Clinical and Translational Imaging, Department of Medicine - DIMED, Padova University Hospital, Padova, Italy
| | - Anna Sara Fraia
- Unit of Advanced Clinical and Translational Imaging, Department of Medicine - DIMED, Padova University Hospital, Padova, Italy
| | - Elena De Zorzi
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, Padova, Italy
| | - Mariele Gatto
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| | - Luana Ienna
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| | - Elena Treppo
- Division of Rheumatology, Department of Medicine (DAME), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy
| | - Danilo Malandrino
- Department of Experimental and Clinical Medicine, University of Firenze, and Interdisciplinary Internal Medicine Unit, Behçet Centre and Lupus Clinic, AOU Careggi Hospital of Florence, Firenze, Italy
| | - Lorenzo Cereser
- Institute of Radiology, Department of Medicine (DAME), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy
| | - Giacomo Emmi
- Department of Experimental and Clinical Medicine, University of Firenze, and Interdisciplinary Internal Medicine Unit, Behçet Centre and Lupus Clinic, AOU Careggi Hospital of Florence, Firenze, Italy
- Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia
| | - Federico Giannelli
- Department of Radiology, Azienda USL Toscana Centro, Mugello Hospital, Borgo San Lorenzo, Italy
| | - Serena Bellani
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, Padova, Italy
| | - Andrea Martini
- Unit of Internal Medicine and Hepatology, Department of Medicine, University-Teaching Hospital of Padova, Padova, Italy
| | - Beatrice Moccaldi
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| | - Anna Ghirardello
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| | - Jérôme Avouac
- Service de Rhumatologie, Hôpital Cochin, APHP, Université Paris Cité Faculté de Santé, Paris, Île-de-France, France
| | - Luca Quartuccio
- Division of Rheumatology, Department of Medicine (DAME), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy
| | - Yannick Allanore
- Service de Rhumatologie, Hôpital Cochin, APHP, Université Paris Cité Faculté de Santé, Paris, Île-de-France, France
| | - Andrea Doria
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| | - Paolo Spagnolo
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, Padova, Italy
| | - Elisabetta Balestro
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, Padova, Italy
| | - Luca Iaccarino
- Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Padova, Italy
| |
Collapse
|
18
|
Murphy E, Liu Y, Matanovic I, Rüscher M, Huang Y, Ly A, Guo S, Zang W, Yan X, Martini A, Timoshenko J, Cuenya BR, Zenyuk IV, Pan X, Spoerke ED, Atanassov P. Elucidating electrochemical nitrate and nitrite reduction over atomically-dispersed transition metal sites. Nat Commun 2023; 14:4554. [PMID: 37507382 PMCID: PMC10382506 DOI: 10.1038/s41467-023-40174-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Accepted: 07/17/2023] [Indexed: 07/30/2023] Open
Abstract
Electrocatalytic reduction of waste nitrates (NO3-) enables the synthesis of ammonia (NH3) in a carbon neutral and decentralized manner. Atomically dispersed metal-nitrogen-carbon (M-N-C) catalysts demonstrate a high catalytic activity and uniquely favor mono-nitrogen products. However, the reaction fundamentals remain largely underexplored. Herein, we report a set of 14; 3d-, 4d-, 5d- and f-block M-N-C catalysts. The selectivity and activity of NO3- reduction to NH3 in neutral media, with a specific focus on deciphering the role of the NO2- intermediate in the reaction cascade, reveals strong correlations (R=0.9) between the NO2- reduction activity and NO3- reduction selectivity for NH3. Moreover, theoretical computations reveal the associative/dissociative adsorption pathways for NO2- evolution, over the normal M-N4 sites and their oxo-form (O-M-N4) for oxyphilic metals. This work provides a platform for designing multi-element NO3RR cascades with single-atom sites or their hybridization with extended catalytic surfaces.
Collapse
Affiliation(s)
- Eamonn Murphy
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA, 92697, USA
| | - Yuanchao Liu
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA, 92697, USA
| | - Ivana Matanovic
- Department of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM, 87131, USA
- Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, 87545, USA
| | - Martina Rüscher
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society, 4-6 Faradayweg, Berlin, 14195, Germany
| | - Ying Huang
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA
| | - Alvin Ly
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA
| | - Shengyuan Guo
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA, 92697, USA
| | - Wenjie Zang
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA
| | - Xingxu Yan
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA
| | - Andrea Martini
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society, 4-6 Faradayweg, Berlin, 14195, Germany
| | - Janis Timoshenko
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society, 4-6 Faradayweg, Berlin, 14195, Germany
| | - Beatriz Roldán Cuenya
- Department of Interface Science, Fritz Haber Institute of the Max Planck Society, 4-6 Faradayweg, Berlin, 14195, Germany
| | - Iryna V Zenyuk
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA, 92697, USA
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA
| | - Xiaoqing Pan
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA
| | - Erik D Spoerke
- Sandia National Laboratories, Albuquerque, NM, 87185, USA
| | - Plamen Atanassov
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA, 92697, USA.
- Department of Materials Science and Engineering, University of California, Irvine, CA, 92697, USA.
| |
Collapse
|
19
|
Guerra P, Martini A, Pontisso P, Angeli P. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma. Cancers (Basel) 2023; 15:3629. [PMID: 37509293 PMCID: PMC10377787 DOI: 10.3390/cancers15143629] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 07/06/2023] [Accepted: 07/11/2023] [Indexed: 07/30/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is a common and aggressive cancer with a high mortality rate. The incidence of HCC is increasing worldwide, and the lack of effective screening programs often results in delayed diagnosis, making it a challenging disease to manage. Immunotherapy has emerged as a promising treatment option for different kinds of cancers, with the potential to stimulate the immune system to target cancer cells. However, the current immunotherapeutic approaches for HCC have shown limited efficacy. Since HCC arises within a complex tumour microenvironment (TME) characterized by the presence of various immune and stromal cell types, the understanding of this interaction is crucial for the identification of effective therapy. In this review, we highlight recent advances in our understanding of the TME of HCC and the immune cells involved in anti-tumour responses, including the identification of new possible targets for immunotherapy. We illustrate a possible classification of HCC based on the tumour immune infiltration and give evidence about the role of SerpinB3, a serine protease inhibitor involved in the regulation of the immune response in different cancers.
Collapse
Affiliation(s)
- Pietro Guerra
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy
| | - Andrea Martini
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy
| | - Patrizia Pontisso
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy
| | - Paolo Angeli
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy
| |
Collapse
|
20
|
Angelini A, Martini A, Begliomini B, Silvestri S. [Malignant mesothelioma in two married couples exposed to asbestos]. Epidemiol Prev 2023; 47:257-262. [PMID: 37846448 DOI: 10.19191/ep23.4-5.a623.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/18/2023]
Abstract
BACKGROUND the relationship between past asbestos exposure and the onset of malignant mesothelioma (MM) is well established. However, defining the exposure is not always easy, as it occurs decades before the onset of the disease. OBJECTIVES this report describes four cases of MM diagnosed in two different married couples, both exposed to asbestos fibers: husbands at work and wives for cohabiting and washing their work overalls. DESIGN case report. METHODS the information was collected through interviews using a semi-structured questionnaire and analyzed by occupational hygienists during the activity of epidemiological surveillance of this disease. The results of the mineral content of asbestos fibers performed on lung parenchymal from one of the female cases are available. RESULTS these two cases show a longer latency in the lesser exposed confirming what an occupational epidemiological study has recently highlighted. CONCLUSIONS whenever good quality information collected during interviews are available, skilled occupational hygienists are able to reconstruct past exposures in quali-quantitative terms.
Collapse
Affiliation(s)
- Alessia Angelini
- Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy;
| | - Andrea Martini
- Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy
| | | | - Stefano Silvestri
- Dipartimento di medicina traslazionale, Università del Piemonte Orientale, Novara, Italy
| |
Collapse
|
21
|
Vimercati L, Cavone D, De Maria L, Caputi A, Pentimone F, Sponselli S, Delvecchio G, Chellini E, Binazzi A, Di Marzio D, Mensi C, Consonni D, Migliore E, Mirabelli D, Angelini A, Martini A, Negro C, D'Agostin F, Grappasonni I, Pascucci C, Benfatto L, Malacarne D, Casotto V, Comiati V, Storchi C, Mangone L, Murano S, Rossin L, Tallarigo F, Vitale F, Verardo M, Eccher S, Madeo G, Staniscia T, Carrozza F, Cozzi I, Romeo E, Pelullo P, Labianca M, Melis M, Cascone G, Marinaccio A, Ferri GM, Serio G. Mesothelioma Risk among Construction Workers According to Job Title: Data from the Italian Mesothelioma Register. Med Lav 2023; 114:e2023025. [PMID: 37309879 DOI: 10.23749/mdl.v114i3.14538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 04/13/2023] [Indexed: 06/14/2023]
Abstract
BACKGROUND An increased risk of mesothelioma has been reported in various countries for construction workers. The Italian National Mesothelioma Registry, from 1993 to 2018, reported exposure exclusively in the construction sector in 2310 cases. We describe the characteristics of these cases according to job title. METHODS We converted into 18 groups the original jobs (N=338) as reported by ISTAT codes ('ATECO 91'). The exposure level was attributed at certain, probable and possible in accordance with the qualitative classification of exposure as reported in the Registry guidelines. Descriptive analysis by jobs highlights the total number of subjects for each single job and certain exposure, in descending order, insulator, plumbing, carpenter, mechanic, bricklayer, electrician, machine operator, plasterer, building contractor, painter and labourer. RESULTS The cases grow for plumbing in the incidence periods 1993-2018, while, as expected, it decreases for insulator. Within each period considered the most numerous cases are always among bricklayers and labourers, these data confirm the prevalence of non-specialised "interchangeable" jobs in Italian construction sector in the past. CONCLUSIONS Despite the 1992 ban, the construction sector still presents an occupational health prevention challenge, circumstances of exposure to asbestos may still occur due to incomplete compliance with prevention and protection measures.
Collapse
Affiliation(s)
- Luigi Vimercati
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Op-erating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Domenica Cavone
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Luigi De Maria
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Antonio Caputi
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Floriana Pentimone
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Stefania Sponselli
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | - Giuseppe Delvecchio
- Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, Regional Oper-ating Center of Puglia (COR Puglia), University of Bari, 70125 Bari, Italy.
| | | | - Alessandra Binazzi
- Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Italian Workers' Com-pensation Authority (INAIL), 00143 Rome, Italy.
| | - Davide Di Marzio
- Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Italian Workers' Com-pensation Authority (INAIL), 00143 Rome, Italy.
| | - Carolina Mensi
- Epidemiology Unit, Regional Operating Center of Lombardia (COR Lombardia), Fondazione IRCCS Ca' Gran-da Ospedale Maggiore Policlinico, 20122 Milano, Italy.
| | - Dario Consonni
- Epidemiology Unit, Regional Operating Center of Lombardia (COR Lombardia), Fondazione IRCCS Ca' Gran-da Ospedale Maggiore Policlinico, 20122 Milano, Italy.
| | - Enrica Migliore
- Unit of Cancer Epidemiology, Regional Operating Center of Piemonte (COR Piemonte), University of Torino and CPO-Piemonte, 10124 Torino, Italy.
| | - Dario Mirabelli
- Unit of Cancer Epidemiology, Regional Operating Center of Piemonte (COR Piemonte), University of Torino and CPO-Piemonte, 10124 Torino, Italy.
| | - Alessia Angelini
- Prevention and Clinical Network, Institute for Cancer Research, Regional Operating Center of Toscana (COR Toscana), 50139 Firenze, Italy.
| | - Andrea Martini
- Prevention and Clinical Network, Institute for Cancer Research, Regional Operating Center of Toscana (COR Toscana), 50139 Firenze, Italy.
| | - Corrado Negro
- Clinical Unit of Occupational Medicine, Regional Operating Center of Friuli-Venezia Giulia (COR Friuli-Venezia Giulia), University of Trieste-Trieste General Hospitals, 34123 Trieste, Italy .
| | - Flavia D'Agostin
- Clinical Unit of Occupational Medicine, Regional Operating Center of Friuli-Venezia Giulia (COR Friuli-Venezia Giulia), University of Trieste-Trieste General Hospitals, 34123 Trieste, Italy .
| | - Iolanda Grappasonni
- Regional Operating Center of Marche (COR Marche), School of Medicinal and Health Products Sciences, Uni-versity of Camerino, 62032 Camerino, Italy.
| | - Cristiana Pascucci
- Regional Operating Center of Marche (COR Marche), School of Medicinal and Health Products Sciences, Uni-versity of Camerino, 62032 Camerino, Italy.
| | - Lucia Benfatto
- Regional Operating Center of Liguria (COR Liguria Regional Operating Center of Liguria (COR Liguria), Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
| | - Davide Malacarne
- Regional Operating Center of Liguria (COR Liguria Regional Operating Center of Liguria (COR Liguria), Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
| | - Veronica Casotto
- Azienda Zero, Epidemiological Department, Regional Operating Center of Veneto (COR Veneto), Veneto Re-gion, 35131 Padova, Italy.
| | - Vera Comiati
- Azienda Zero, Epidemiological Department, Regional Operating Center of Veneto (COR Veneto), Veneto Re-gion, 35131 Padova, Italy.
| | - Cinzia Storchi
- Health Local Unit, Public Health Department, Regional Operating Center of Emilia-Romagna (COR Emi-lia-Romagna), 42020 Reggio Emilia, Italy, Epidemiology Unit, AUSL-IRCCS di Reggio Emilia, Italy.
| | - Lucia Mangone
- Health Local Unit, Public Health Department, Regional Operating Center of Emilia-Romagna (COR Emi-lia-Romagna), 42020 Reggio Emilia, Italy, Epidemiology Unit, AUSL-IRCCS di Reggio Emilia, Italy.
| | - Stefano Murano
- Occupational Medicine Unit, Alto Adige Health Authority, Regional Operating Center of Autonomous Province of Bolzano (COR A.P. of Bolzano), 39100 Bolzano, Italy.
| | - Lucia Rossin
- Occupational Medicine Unit, Alto Adige Health Authority, Regional Operating Center of Autonomous Province of Bolzano (COR A.P. of Bolzano), 39100 Bolzano, Italy.
| | - Federico Tallarigo
- Public Health Unit, Regional Operating Center of Calabria (COR Calabria), 88900 Crotone, Italy.
| | - Filomena Vitale
- Public Health Unit, Regional Operating Center of Calabria (COR Calabria), 88900 Crotone, Italy.
| | - Marina Verardo
- Valle d'Aosta Health Local Unit, Regional Operating Center of Valle d'Aosta (COR Valle d'Aosta), 11100 Aosta, Italy.
| | - Silvia Eccher
- Hygiene and Occupational Medicine, Provincial Unit of Health, Regional Operating Center o Autonomous Province of Trento (COR A.P. of Trento), 38100 Trento, Italy.
| | - Gabriella Madeo
- Center of Umbria (COR Umbria), Servizio Prevenzione, Sanità Veterinaria e Sicurezza Alimentare-Regione Umbria, 06126 Perugia, Italy.
| | - Tommaso Staniscia
- Occupational Medicine Unit, Health Local Unit, Regional Operating Center of Abruzzo (COR Abruzzo), 65121 Pescara, Italy.
| | - Francesco Carrozza
- Oncology Unit, Cardarelli Hospital, Regional Operating Center of Molise (COR Molise), 86100 Campobasso, It-aly.
| | - Ilaria Cozzi
- Regional Operating Center of Lazio (COR Lazio), Department of Epidemiology, Epidemiology Lazio Regional Health Service, ASL Roma 1, 00147 Roma, Italy.
| | - Elisa Romeo
- Regional Operating Center of Lazio (COR Lazio), Department of Epidemiology, Epidemiology Lazio Regional Health Service, ASL Roma 1, 00147 Roma, Italy.
| | - Paola Pelullo
- Department of Experimental Medicine, "Luigi Vanvitelli" University, Regional Operating Center of Campania (COR Campania), 80138 Napoli, Italy.
| | - Michele Labianca
- Epidemiologic Regional Center, Regional Operating Center of Basilicata (COR Basilicata), 85100 Potenza, Italy.
| | - Massimo Melis
- Regional Epidemiological Center, Regional Operating Center of Sardegna (COR Sardegna), 09125 Cagliari, Ita-ly.
| | - Giuseppe Cascone
- Cancer Registry ASP Ragusa and Sicilia Regional Epidemiological Observatory, Regional Operating Center of Sicilia (COR Sicilia), 97100 Ragusa, Italy.
| | - Alessandro Marinaccio
- Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Italian Workers' Com-pensation Authority (INAIL), 00143 Rome, Italy.
| | | | - Gabriella Serio
- Department of Emergency and Organ Transplantation (DETO), Pathological Anatomy Section, University of Bari Aldo Moro, Bari, Italy.
| |
Collapse
|
22
|
Adachi I, Adamczyk K, Aggarwal L, Ahmed H, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Aushev T, Aushev V, Bae H, Bahinipati S, Bambade P, Banerjee S, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhuyan B, Bianchi F, Bilka T, Biswas D, Bodrov D, Bolz A, Borah J, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Chang MC, Chang P, Cheaib R, Cheema P, Chekelian V, Chen C, Chen YQ, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cunliffe S, Das S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dubey S, Dujany G, Ecker P, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finck C, Finocchiaro G, Fodor A, Forti F, Fulsom BG, Ganiev E, Garcia-Hernandez M, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Granderath S, Graziani E, Greenwald D, Gruberová Z, Gu T, Gudkova K, Guilliams J, Haigh H, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hohmann M, Hsu CL, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Joo KK, Junkerkalefeld H, Kakuno H, Kaliyar AB, Kang KH, Kang S, Karl R, Karyan G, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumara K, Kunigo T, Kuzmin A, Kwon YJ, Lacaprara S, Lam T, Lanceri L, Lange JS, Laurenza M, Lautenbach K, Leboucher R, Le Diberder FR, Leitl P, Li C, Li LK, Libby J, Lieret K, Liptak Z, Liu QY, Liventsev D, Longo S, Lozar A, Lueck T, Luo T, Lyu C, Maggiora M, Maiti R, Maity S, Manfredi R, Manoni E, Marcello S, Marinas C, Martel L, Martini A, Martinov T, Massaccesi L, Masuda M, Matsuoka K, Matvienko D, Maurya SK, McKenna JA, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mizuk R, Mohanty GB, Molina-Gonzalez N, Moneta S, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakamura KR, Nakao M, Nakayama H, Nakazawa Y, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nazaryan G, Nisar NK, Nishida S, Ogawa S, Ono H, Onuki Y, Oskin P, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Parham K, Park H, Park SH, Paschen B, Passeri A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Piccolo M, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raeuber G, Raiz S, Ramirez Morales A, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Robertson SH, Rodríguez Pérez D, Roney JM, Rostomyan A, Rout N, Russo G, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shen CP, Shillington T, Shiu JG, Sibidanov A, Simon F, Singh JB, Skorupa J, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sue Y, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Takizawa M, Tamponi U, Tanida K, Tanigawa H, Taniguchi N, Tenchini F, Thaller A, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varvell KE, Vinokurova A, Vitale L, Vobbilisetti V, Wakeling HM, Wang E, Wang MZ, Wang XL, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yin JH, Yook YM, Yoshihara K, Yuan CZ, Yusa Y, Zani L, Zhang Y, Zhilich V, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Search for an Invisible Z^{'} in a Final State with Two Muons and Missing Energy at Belle II. Phys Rev Lett 2023; 130:231801. [PMID: 37354391 DOI: 10.1103/physrevlett.130.231801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 04/19/2023] [Indexed: 06/26/2023]
Abstract
The L_{μ}-L_{τ} extension of the standard model predicts the existence of a lepton-flavor-universality-violating Z^{'} boson that couples only to the heavier lepton families. We search for such a Z^{'} through its invisible decay in the process e^{+}e^{-}→μ^{+}μ^{-}Z^{'}. We use a sample of electron-positron collisions at a center-of-mass energy of 10.58 GeV collected by the Belle II experiment in 2019-2020, corresponding to an integrated luminosity of 79.7 fb^{-1}. We find no excess over the expected standard-model background. We set 90%-confidence-level upper limits on the cross section for this process as well as on the coupling of the model, which ranges from 3×10^{-3} at low Z^{'} masses to 1 at Z^{'} masses of 8 GeV/c^{2}.
Collapse
|
23
|
Zanatta E, Martini A, Depascale R, Gamba A, Tonello M, Gatto M, Giraudo C, Balestro E, Doria A, Iaccarino L. CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies. Diagnostics (Basel) 2023; 13:diagnostics13101715. [PMID: 37238199 DOI: 10.3390/diagnostics13101715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 05/02/2023] [Accepted: 05/10/2023] [Indexed: 05/28/2023] Open
Abstract
OBJECTIVES To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). METHODS Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. RESULTS ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7-399.07] vs. 48.4 [29.9-147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8-520.5] vs. 162 [75.4-255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307-958.7] vs. 207.1 [149.3-381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002-1.011], p = 0.005). CONCLUSIONS Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD.
Collapse
Affiliation(s)
- Elisabetta Zanatta
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Andrea Martini
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Roberto Depascale
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Anna Gamba
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Marta Tonello
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Mariele Gatto
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Chiara Giraudo
- Unit of Advanced Clinical and Translational Imaging, Department of Medicine-DIMED, Padova University Hospital, 35128 Padova, Italy
| | - Elisabetta Balestro
- Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, 35128 Padova, Italy
| | - Andrea Doria
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| | - Luca Iaccarino
- Rheumatology Unit, Department of Medicine, University Hospital of Padova, 35128 Padova, Italy
| |
Collapse
|
24
|
Lai YT, Adachi I, Aihara H, Al Said S, Asner DM, Atmacan H, Aulchenko V, Aushev T, Ayad R, Babu V, Bahinipati S, Behera P, Belous K, Bennett J, Bessner M, Bhuyan B, Bilka T, Bobrov A, Borah J, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Campajola M, Červenkov D, Chang MC, Chang P, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho HE, Cho K, Cho SJ, Choi SK, Choi Y, Cinabro D, Cunliffe S, Czank T, Das S, De Nardo G, De Pietro G, Dhamija R, Di Capua F, Dingfelder J, Doležal Z, Dong TV, Ferber T, Fulsom BG, Garg R, Gaur V, Gabyshev N, Giri A, Goldenzweig P, Graziani E, Gu T, Guan Y, Gudkova K, Hadjivasiliou C, Halder S, Hartbrich O, Hayasaka K, Hayashii H, Higuchi T, Hou WS, Hsu CL, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jacobs WW, Jang EJ, Jia S, Jin Y, Kaliyar AB, Kang KH, Kim CH, Kim DY, Kim KH, Kim YK, Kinoshita K, Kodyš P, Konno T, Korobov A, Korpar S, Kovalenko E, Križan P, Krokovny P, Kumar M, Kumar R, Kumara K, Kuzmin A, Kwon YJ, Lam T, Lange JS, Laurenza M, Lee SC, Levit D, Li J, Li LK, Li YB, Li Gioi L, Libby J, Lieret K, Liventsev D, Martini A, Masuda M, Matvienko D, Meier F, Merola M, Metzner F, Mizuk R, Mohanty GB, Moon TJ, Mrvar M, Mussa R, Nakao M, Natochii A, Nayak L, Nisar NK, Nishida S, Ogawa S, Pakhlova G, Pang T, Pardi S, Park H, Park SH, Passeri A, Patra S, Paul S, Pedlar TK, Pestotnik R, Piilonen LE, Podobnik T, Prencipe E, Prim MT, Rostomyan A, Rout N, Russo G, Sahoo D, Sakai Y, Sandilya S, Sangal A, Santelj L, Sanuki T, Savinov V, Schnell G, Schueler J, Schwanda C, Seino Y, Senyo K, Sevior ME, Shapkin M, Sharma C, Shen CP, Shiu JG, Singh JB, Sokolov A, Solovieva E, Starič M, Stottler ZS, Strube JF, Sumihama M, Sumisawa K, Sutcliffe W, Takizawa M, Tamponi U, Tanida K, Tenchini F, Trabelsi K, Uglov T, Unno Y, Uno K, Uno S, Urquijo P, van Tonder R, Varner G, Varvell KE, Vinokurova A, Vossen A, Waheed E, Wang CH, Wang XL, Watanabe M, Watanuki S, Won E, Yabsley BD, Yan W, Yang SB, Ye H, Yelton J, Zhai Y, Zhang ZP, Zhilich V, Zhukova V. First Measurement of the B^{+}→π^{+}π^{0}π^{0} Branching Fraction and CP Asymmetry. Phys Rev Lett 2023; 130:181804. [PMID: 37204904 DOI: 10.1103/physrevlett.130.181804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Accepted: 03/27/2023] [Indexed: 05/21/2023]
Abstract
We study B^{+}→π^{+}π^{0}π^{0} using 711 fb^{-1} of data collected at the ϒ(4S) resonance with the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider. We measure an inclusive branching fraction of (19.0±1.5±1.4)×10^{-6} and an inclusive CP asymmetry of (9.2±6.8±0.7)%, where the first uncertainties are statistical and the second are systematic, and a B^{+}→ρ(770)^{+}π^{0} branching fraction of (11.2±1.1±0.9_{-1.6}^{+0.8})×10^{-6}, where the third uncertainty is due to possible interference with B^{+}→ρ(1450)^{+}π^{0}. We present the first observation of a structure around 1 GeV/c^{2} in the π^{0}π^{0} mass spectrum, with a significance of 6.4σ, and measure a branching fraction to be (6.9±0.9±0.6)×10^{-6}. We also report a measurement of local CP asymmetry in this structure.
Collapse
|
25
|
Adachi I, Adamczyk K, Aggarwal L, Ahmed H, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Aushev T, Aushev V, Bae H, Bahinipati S, Bambade P, Banerjee S, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhuyan B, Bianchi F, Bilka T, Bilokin S, Biswas D, Bodrov D, Bolz A, Borah J, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Chang MC, Chang P, Cheaib R, Cheema P, Chekelian V, Chen YQ, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cunliffe S, Das S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dubey S, Dujany G, Ecker P, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finck C, Finocchiaro G, Flood K, Fodor A, Forti F, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Gradl W, Granderath S, Graziani E, Greenwald D, Gruberová Z, Gu T, Gudkova K, Guilliams J, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hohmann M, Hsu CL, Humair T, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Joo KK, Junkerkalefeld H, Kakuno H, Kaliyar AB, Kandra J, Kang KH, Kang S, Karl R, Karyan G, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar R, Kumara K, Kunigo T, Kuzmin A, Kwon YJ, Lacaprara S, Lam T, Lanceri L, Lange JS, Laurenza M, Lautenbach K, Leboucher R, Le Diberder FR, Leitl P, Lewis PM, Li C, Li LK, Li YB, Libby J, Lieret K, Liptak Z, Liu QY, Liventsev D, Longo S, Lozar A, Lueck T, Luo T, Lyu C, Maggiora M, Maiti R, Maity S, Manfredi R, Manoni E, Manthei A, Marcello S, Marinas C, Martel L, Martini A, Martinov T, Massaccesi L, Masuda M, Matsuda T, Matsuoka K, Matvienko D, Maurya SK, McKenna JA, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mizuk R, Mohanty GB, Molina-Gonzalez N, Moneta S, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakamura KR, Nakao M, Nakayama H, Nakazawa Y, Narimani Charan A, Naruki M, Natochii A, Nayak L, Nayak M, Nazaryan G, Niebuhr C, Nisar NK, Nishida S, Ogawa S, Ono H, Onuki Y, Oskin P, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Parham K, Park H, Park SH, Paschen B, Passeri A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piccolo M, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raeuber G, Raiz S, Ramirez Morales A, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Robertson SH, Rodríguez Pérez D, Roney JM, Rostomyan A, Rout N, Russo G, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shen CP, Shi XD, Shillington T, Shiu JG, Shwartz B, Sibidanov A, Simon F, Singh JB, Skorupa J, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sue Y, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Takizawa M, Tamponi U, Tanida K, Tanigawa H, Tenchini F, Thaller A, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vobbilisetti V, Wakeling HM, Wang E, Wang MZ, Wang XL, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Wiechczynski J, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yelton J, Yin JH, Yook YM, Yoshihara K, Yuan CZ, Yusa Y, Zani L, Zhang Y, Zhilich V, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Search for Lepton-Flavor-Violating τ Decays to a Lepton and an Invisible Boson at Belle II. Phys Rev Lett 2023; 130:181803. [PMID: 37204890 DOI: 10.1103/physrevlett.130.181803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 02/23/2023] [Indexed: 05/21/2023]
Abstract
We search for lepton-flavor-violating τ^{-}→e^{-}α and τ^{-}→μ^{-}α decays, where α is an invisible spin-0 boson. The search uses electron-positron collisions at 10.58 GeV center-of-mass energy with an integrated luminosity of 62.8 fb^{-1}, produced by the SuperKEKB collider and collected with the Belle II detector. We search for an excess in the lepton-energy spectrum of the known τ^{-}→e^{-}ν[over ¯]_{e}ν_{τ} and τ^{-}→μ^{-}ν[over ¯]_{μ}ν_{τ} decays. We report 95% confidence-level upper limits on the branching-fraction ratio B(τ^{-}→e^{-}α)/B(τ^{-}→e^{-}ν[over ¯]_{e}ν_{τ}) in the range (1.1-9.7)×10^{-3} and on B(τ^{-}→μ^{-}α)/B(τ^{-}→μ^{-}ν[over ¯]_{μ}ν_{τ}) in the range (0.7-12.2)×10^{-3} for α masses between 0 and 1.6 GeV/c^{2}. These results provide the most stringent bounds on invisible boson production from τ decays.
Collapse
|
26
|
Adachi I, Aggarwal L, Ahmed H, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Aushev T, Aushev V, Bae H, Bambade P, Banerjee S, Baudot J, Bauer M, Beaubien A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhuyan B, Bianchi F, Bilka T, Biswas D, Bodrov D, Bolz A, Borah J, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Chang MC, Cheema P, Chekelian V, Chen YQ, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cunliffe S, Das S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dreyer S, Dubey S, Dujany G, Eliachevitch M, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finocchiaro G, Fodor A, Forti F, Fulsom BG, Ganiev E, Gaur V, Gaz A, Gellrich A, Ghevondyan G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Granderath S, Graziani E, Greenwald D, Gu T, Guan Y, Gudkova K, Guilliams J, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hirata H, Hohmann M, Hsu CL, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Joo KK, Junkerkalefeld H, Kaliyar AB, Kang KH, Karl R, Karyan G, Ketter C, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kumar R, Kumara K, Kunigo T, Kuzmin A, Kwon YJ, Lacaprara S, Lam T, Lanceri L, Lange JS, Laurenza M, Lautenbach K, Leboucher R, Lewis PM, Li C, Li LK, Libby J, Lieret K, Liptak Z, Liu QY, Liventsev D, Longo S, Lozar A, Lueck T, Lyu C, Maggiora M, Maiti R, Manfredi R, Manoni E, Marcello S, Marinas C, Martel L, Martini A, Martinov T, Massaccesi L, Masuda M, Matsuoka K, Maurya SK, McKenna JA, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mizuk R, Molina-Gonzalez N, Moneta S, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakao M, Nakazawa Y, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nazaryan G, Nisar NK, Ogawa S, Ono H, Onuki Y, Oskin P, Paladino A, Panta A, Paoloni E, Pardi S, Park H, Park SH, Paschen B, Passeri A, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Piccolo M, Piilonen LE, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Raiz S, Ramirez Morales A, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Robertson SH, Roney JM, Rostomyan A, Rout N, Russo G, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shen CP, Shi XD, Shillington T, Sibidanov A, Singh JB, Skorupa J, Sobie RJ, Soffer A, Solovieva E, Spataro S, Starič M, Stefkova S, Stottler ZS, Stroili R, Sue Y, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Takizawa M, Tanida K, Tanigawa H, Tenchini F, Thaller A, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Vinokurova A, Vitale L, Vobbilisetti V, Wakeling HM, Wang E, Wang MZ, Warburton A, Watanuki S, Welsch M, Wessel C, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yelton J, Yin JH, Yook YM, Yoshihara K, Yuan CZ, Zani L, Zhang Y, Zhou XY, Zhukova VI, Žlebčík R. Observation of e^{+}e^{-}→ωχ_{bJ}(1P) and Search for X_{b}→ωϒ(1S) at sqrt[s] near 10.75 GeV. Phys Rev Lett 2023; 130:091902. [PMID: 36930912 DOI: 10.1103/physrevlett.130.091902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 01/25/2023] [Indexed: 06/18/2023]
Abstract
We study the processes e^{+}e^{-}→ωχ_{bJ}(1P) (J=0, 1, or 2) using samples at center-of-mass energies sqrt[s]=10.701, 10.745, and 10.805 GeV, corresponding to 1.6, 9.8, and 4.7 fb^{-1} of integrated luminosity, respectively. These data were collected with the Belle II detector during special operations of the SuperKEKB collider above the ϒ(4S) resonance. We report the first observation of ωχ_{bJ}(1P) signals at sqrt[s]=10.745 GeV. By combining Belle II data with Belle results at sqrt[s]=10.867 GeV, we find energy dependencies of the Born cross sections for e^{+}e^{-}→ωχ_{b1,b2}(1P) to be consistent with the shape of the ϒ(10753) state. These data indicate that the internal structures of the ϒ(10753) and ϒ(10860) states may differ. Including data at sqrt[s]=10.653 GeV, we also search for the bottomonium equivalent of the X(3872) state decaying into ωϒ(1S). No significant signal is observed for masses between 10.45 and 10.65 GeV/c^{2}.
Collapse
|
27
|
Abudinén F, Aggarwal L, Ahmed H, Ahn JK, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Babu V, Bae H, Bambade P, Banerjee S, Bansal S, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhardwaj V, Bianchi F, Bilka T, Biswas D, Bodrov D, Bolz A, Bonvicini G, Bozek A, Bračko M, Branchini P, Briere RA, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Chang MC, Chang P, Cheaib R, Cheema P, Chen C, Chen YQ, Chen YT, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dujany G, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finocchiaro G, Flood K, Fodor A, Forti F, Frey A, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Gaz A, Gellrich A, Ghevondyan G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Gradl W, Granderath S, Greenwald D, Gu T, Guan Y, Gudkova K, Guilliams J, Halder S, Hara K, Hartbrich O, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hohmann M, Humair T, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Iwasaki Y, Jackson P, Jacobs WW, Jaffe DE, Ji QP, Jin Y, Junkerkalefeld H, Kaleta M, Kandra J, Kang KH, Karl R, Karyan G, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar R, Kumara K, Kunigo T, Kwon YJ, Lacaprara S, Lam T, Lanceri L, Lange JS, Laurenza M, Leboucher R, Lee SC, Leitl P, Levit D, Li LK, Li SX, Li YB, Libby J, Liptak Z, Liu QY, Liventsev D, Longo S, Lueck T, Lyu C, Maggiora M, Maiti R, Maity S, Manfredi R, Manoni E, Marcello S, Marinas C, Martel L, Martini A, Massaccesi L, Masuda M, Matsuoka K, Matvienko D, McKenna JA, Meier F, Merola M, Milesi M, Miller C, Miyabayashi K, Mohanty GB, Molina-Gonzalez N, Moneta S, Moon H, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakao M, Nakayama H, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nazaryan G, Niebuhr C, Nisar NK, Nishida S, Nishimura K, Ono H, Oskin P, Oxford ER, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Parham K, Park H, Park SH, Passeri A, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raiz S, Reif M, Reiter S, Ripp-Baudot I, Rizzo G, Robertson SH, Roney JM, Rostomyan A, Rout N, Russo G, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schwanda C, Schwartz AJ, Seino Y, Selce A, Senyo K, Serrano J, Sfienti C, Shen CP, Shillington T, Shiu JG, Sibidanov A, Simon F, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stroili R, Strube J, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Takahashi M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Taniguchi N, Tenchini F, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vobbilisetti V, Waheed E, Wakeling HM, Wang E, Wang MZ, Wang XL, Warburton A, Watanuki S, Welsch M, Wessel C, Wiechczynski J, Windel H, Won E, Xu XP, Yabsley BD, Yamada S, Yang SB, Ye H, Yelton J, Yin JH, Yoshihara K, Yusa Y, Zhang Y, Zhilich V, Zhou QD, Zhukova VI, Žlebčík R. Measurement of the Λ_{c}^{+} Lifetime. Phys Rev Lett 2023; 130:071802. [PMID: 36867815 DOI: 10.1103/physrevlett.130.071802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 07/25/2022] [Indexed: 06/18/2023]
Abstract
An absolute measurement of the Λ_{c}^{+} lifetime is reported using Λ_{c}^{+}→pK^{-}π^{+} decays in events reconstructed from data collected by the Belle II experiment at the SuperKEKB asymmetric-energy electron-positron collider. The total integrated luminosity of the data sample, which was collected at center-of-mass energies at or near the ϒ(4S) resonance, is 207.2 fb^{-1}. The result, τ(Λ_{c}^{+})=203.20±0.89±0.77 fs, where the first uncertainty is statistical and the second systematic, is the most precise measurement to date and is consistent with previous determinations.
Collapse
|
28
|
Abudinén F, Adachi I, Aggarwal L, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Babu V, Bahinipati S, Bambade P, Banerjee S, Bansal S, Baudot J, Baur A, Beaubien A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bertholet E, Bessner M, Bhuyan B, Bianchi F, Bilka T, Biswas D, Bobrov A, Bodrov D, Bolz A, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Bussino S, Campajola M, Casarosa G, Cecchi C, Chekelian V, Chen C, Chen YQ, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cunliffe S, Dattola F, de Marino G, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dubey S, Dujany G, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finck C, Finocchiaro G, Flood K, Fodor A, Forti F, Frey A, Fulsom BG, Ganiev E, Garcia-Hernandez M, Gaur V, Gaz A, Gellrich A, Giordano R, Giri A, Gobbo B, Godang R, Goldenzweig P, Gradl W, Granderath S, Graziani E, Greenwald D, Gu T, Gudkova K, Guilliams J, Hadjivasiliou C, Hara K, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hoek M, Hohmann M, Hsu CL, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Junkerkalefeld H, Kakuno H, Kaliyar AB, Kandra J, Kang KH, Karl R, Karyan G, Kawasaki T, Ketter C, Kichimi H, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar R, Kumara K, Kunigo T, Kwon YJ, Lacaprara S, Lai YT, Lam T, Lange JS, Laurenza M, Leboucher R, Lee SC, Li LK, Li YB, Libby J, Lieret K, Liu QY, Liventsev D, Longo S, Lozar A, Lueck T, Lyu C, Maggiora M, Maiti R, Maity S, Manfredi R, Manoni E, Marcello S, Marinas C, Martel L, Martini A, Massaccesi L, Masuda M, Matsuoka K, McKenna JA, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mohanty GB, Molina-Gonzalez N, Moneta S, Moon H, Mrvar M, Nakamura I, Nakamura KR, Nakao M, Nakayama H, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nisar NK, Nishida S, Nishimura K, Ogawa S, Ono H, Oskin P, Pakhlova G, Paladino A, Panta A, Pardi S, Parham K, Park H, Park SH, Passeri A, Patra S, Paul S, Pedlar TK, Piccolo M, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raiz S, Ramirez Morales A, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Robertson SH, Rodríguez Pérez D, Roney JM, Rostomyan A, Rout N, Sahoo D, Sanders DA, Sandilya S, Santelj L, Sato Y, Scavino B, Schueler J, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shillington T, Shiu JG, Sibidanov A, Simon F, Singh JB, Skorupa J, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Tenchini F, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vobbilisetti V, Waheed E, Wakeling HM, Wang E, Wang MZ, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Windel H, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yin JH, Yoshihara K, Yuan CZ, Yusa Y, Zani L, Zhang Y, Zhilich V, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Search for a Dark Photon and an Invisible Dark Higgs Boson in μ^{+}μ^{-} and Missing Energy Final States with the Belle II Experiment. Phys Rev Lett 2023; 130:071804. [PMID: 36867830 DOI: 10.1103/physrevlett.130.071804] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Accepted: 11/29/2022] [Indexed: 06/18/2023]
Abstract
The dark photon A^{'} and the dark Higgs boson h^{'} are hypothetical particles predicted in many dark sector models. We search for the simultaneous production of A^{'} and h^{'} in the dark Higgsstrahlung process e^{+}e^{-}→A^{'}h^{'} with A^{'}→μ^{+}μ^{-} and h^{'} invisible in electron-positron collisions at a center-of-mass energy of 10.58 GeV in data collected by the Belle II experiment in 2019. With an integrated luminosity of 8.34 fb^{-1}, we observe no evidence for signal. We obtain exclusion limits at 90% Bayesian credibility in the range of 1.7-5.0 fb on the cross section and in the range of 1.7×10^{-8}-200×10^{-8} on the effective coupling ϵ^{2}×α_{D} for the A^{'} mass in the range of 4.0 GeV/c^{2}<M_{A^{'}}<9.7 GeV/c^{2} and for the h^{'} mass M_{h^{'}}<M_{A^{'}}, where ϵ is the mixing strength between the standard model and the dark photon and α_{D} is the coupling of the dark photon to the dark Higgs boson. Our limits are the first in this mass range.
Collapse
|
29
|
Basile G, Gallioli A, Verri P, Martini A, Territo A, Sanguedolce F, Fontanet S, Aumatell J, Uleri A, Rodriguez-Faba O, Palou J, Breda A. Follow-up intensity scheme for upper tract urothelial carcinoma after nephron-sparing surgery. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00966-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
30
|
Contieri R, Martini A, Beatrici E, Frego N, Diana P, Paciotti M, Mancon S, Lazzeri M, Saita A, Lughezzani G, Buffi N, Casale P, Kamat A, Hurle R. Implementing the Active Surveillance (AS) follow-up schedule for low-grade Non- Muscle-Invasive Bladder Cancer (NMIBC) tumors. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00657-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
31
|
Gaboardi F, Martini A, Nocera L, Proietti S, Russo A. Detrusor apron sparing. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01378-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
32
|
Baboudjian M, Gondran-Tellier B, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, Beauval JB, Roumeguere T, Simone G, Benamran D, Fourcade A, Fiard G, Van Den Bergh R, Peltier A, Ploussard G. MRI-based t-staging to predict biochemical recurrence after radical prostatectomy: A step towards the iTNM classification. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01278-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
33
|
Fallara G, Martini A, Rosiello G, Belladelli F, Musso G, Cei F, Basile G, Re C, Cignoli D, De Cobelli F, Brembilla G, Marandino L, Raggi D, Gandaglia G, Mazzone E, Moschini M, Stabile A, Briganti A, Necchi A, Montorsi F, Salonia A, Larcher A, Capitanio U. Defining the most useful intermediate endpoint for overall survival in intermediate and high-risk clear cell carcinoma. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00517-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
34
|
Martini A, Wever L, Soeterik T, Rakauskas A, Fankhauser C, Grogg J, Checcucci E, Ploussard G, Qiang P, Affentranger A, Marra G, Ettala O, Zattoni F, Falagario U, De Angelis M, Kesch C, Apfelbeck M, Al-Hammouri T, Kretschmer A, Kasivisvanathan V, Preisser F, Olivier J, Radtke J, Carrieri G, Jambor I, Gontero P, Briganti A, Macek P, Chiu P, Hermanns T, Van Den Bergh R, Gandaglia G, Valerio M. Unilateral pelvic lymph node dissection in prostate cancer patients diagnosed in the era of MRI-targeted biopsy: A study that challenges the dogma. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02492-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
35
|
Toneatto L, Gandaglia G, Stabile A, Mazzone E, Rosiello G, Martini A, Bravi C, Cirulli G, Pellegrino A, De Angelis M, Montorsi F, Briganti A. The key role of concomitant androgen-deprivation therapy on the efficacy of imaging guided treatments in men with biochemical recurrent prostate cancer after radical prostatectomy and positive 68Ga-PSMA PET/CT scan. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01091-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
36
|
Nocera L, Basile G, Leni R, de Angelis M, Martini A, Avesani G, Scuderi S, Gandaglia G, Dehò F, Gallina A, Raggi D, Marandino L, Necchi A, Montorsi F, Briganti A, Moschini M. The impact of variant histology on the probability of lymph node involvement at imaging: CT scan vs FDG PET. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01023-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
37
|
Lonati C, Carando R, Martini A, Simeone C, Suardi N, Zamboni S, Simone G, Afferi L, Fankhauser C, Mattei A, Álvarez-Maestro M, Briganti A, Montorsi F, Moschini M. Independent predictors and patterns of early and late recurrence after radical cystectomy for bladder cancer: a multicenter collaboration. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01114-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
38
|
Re C, Rosiello G, Fallara G, Basile G, Cignoli D, Martini A, De Cobelli F, Brembilla G, Nocera L, Belladelli F, Colandrea G, Canibus D, Musso G, Cei F, Matloob R, Briganti A, Bertini R, Necchi A, Raggi D, Karakiewicz P, Montorsi F, Salonia A, Larcher A, Capitanio U. Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01256-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Cirulli G, Rosiello G, Mazzone E, Fossati N, Barletta F, Scuderi S, Robesti D, Gandaglia G, Toneatto L, Colandrea G, Leni R, D’Ambrosio L, Pellegrino A, Quarta L, Gallina A, Cucchiara V, Martini A, Comana S, Stabile A, Camisassa E, Dehò F, Montorsi F, Briganti A. Increased awareness of surgical outcomes improves long-term functional outcomes after robot-assisted radical prostatectomy. A prospective assessment following implementation of prospective data collection. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01250-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
40
|
Scarcella S, Bravi C, Piazza P, Mottaran A, Sarchi L, Paciotti M, Nocera L, Martini A, Piro A, Puliatti S, Beatrici V, De Groote R, Briganti A, Montorsi F, Mottrie A. Validating the comprehensive complication index for assessing cumulative morbidity after robot-assisted radical cystectomy: results from a high-volume institution. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01130-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
41
|
Bravi C, Mazzone E, Dell’Oglio P, Moschovas MC, Martini A, Rosiello G, Piazza P, Mottaran A, Paciotti M, Sarchi L, Puliatti S, Knipper S, De Groote R, Schiavina R, Rocco B, Galfano A, Briganti A, Montorsi F, Patel V, Mottrie A. A nomogram to predict pathologic T2 stage in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric mri: results from a multi-institutional collaboration. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01169-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Avesani G, Mazzone E, Robesti D, Gandaglia G, Stabile A, Scuderi S, Martini A, Bravi C, Rosiello G, Nocera L, Sorce G, Pellegrino F, Cirulli G, D’Ambrosio L, Necchi A, Raggi D, Marandino L, Montorsi F, Briganti A. Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01087-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
43
|
Fallara G, Rosiello G, Necchi A, Raggi D, Cazzaniga W, Martini A, Basile G, Cignoli D, Colandrea G, Baiamonte G, Belladelli F, Musso G, Cei F, Giancristofaro C, Ieva A, Canibus D, Briganti A, Bertini R, Montorsi F, Salonia A, Larcher A, Capitanio U. Oncologic outcomes in patients diagnosed with PT3A non-metastatic renal cell cancer according to renal vein thrombus or fat invasion. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01257-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
44
|
Martini A, Leni R, Pellegrino F, Basile G, Avesani G, Scuderi S, Nocera L, Rosiello G, Gandaglia G, Montorsi F, Briganti A, Gallina A, Moschini M. Acute kidney injury and its duration in patients treated with radical cystectomy in the enhanced recovery after surgery era: optimizing the selection of patients for restrictive fluid therapy. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01126-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
45
|
Moscadelli A, Martini A, Angelini A, Baldassarre A, Lorini C, Bonaccorsi G, Cacciarini V, Rosselli A, Chellini E. [Mortality study in a cohort of entertainment workers]. G Ital Med Lav Ergon 2022; 44:360-359. [PMID: 36622824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Accepted: 09/01/2022] [Indexed: 01/10/2023]
Abstract
SUMMARY Introduction. Malignant mesotheliomas have been observed in entertainment workers in the last decades. They have been evaluated as occupationally exposed to asbestos contained in tools used for fireproof and sound-absorbing purposes. Aim of the study. To evaluate the mortality of workers engaged in a Florentine theatre where a large quantity of asbestos was found in the '80s, put in place 20 years earlier. Methods. It is a cohort study on entertainment workers with follow-up period ranged from 1-1-1970 till 31-12-2018. Standardized Mortality Ratios (SMRs) and their 95% Confidence Intervals (95% IC) were calculated by gender and job ("manual workers" and "all other jobs"), using age and sex specific mortality rates of Tuscan population. Results. The cohort includes 826 workers (389 manual workers and 437 engaged in other jobs) engaged by the Florentine theatre between 01/01/1937 and 31/12/1990. Excesses of mortality for all causes are observed in manual workers, either males (301 cases; SMR 304,0; 95% IC 271,5-340,3) or females (86 cases; SMR 429,8; 95% IC 348,0-531,0). The group of the other workers presents deficits of mortality by all causes, cancers and cardiovascular diseases in both genders. One death for pleural cancer is observed in a manual worker. Discussion. The results are in line with previous observations in similar occupations. In the examined Florentine theatre the asbestos exposures were important only for the manual workers who worked in the technical rooms characterized by the presence of friable asbestos sprinkled and in a bad state of maintenance.
Collapse
Affiliation(s)
- Andrea Moscadelli
- Scuola di specializzazione in Igiene e Medicina preventiva, Università degli Studi di Firenze
| | - Andrea Martini
- Struttura Semplice Epidemiologia dell'Ambiente e del lavoro, ISPRO, Firenze
| | - Alessia Angelini
- Struttura Semplice Epidemiologia dell'Ambiente e del lavoro, ISPRO, Firenze
| | | | - Chiara Lorini
- Dipartimento di Scienze della Salute, Università degli Studi di Firenze
| | | | | | - Annalisa Rosselli
- Struttura Semplice Epidemiologia dell'Ambiente e del lavoro, ISPRO, Firenze
| | | |
Collapse
|
46
|
Jeon H, Kang K, Park H, Adachi I, Aihara H, Al Said S, Asner D, Atmacan H, Aushev T, Ayad R, Babu V, Bahinipati S, Behera P, Belous K, Bennett J, Bernlochner F, Bessner M, Bhardwaj V, Bhuyan B, Bilka T, Bobrov A, Bodrov D, Borah J, Bozek A, Bračko M, Branchini P, Browder T, Budano A, Campajola M, Červenkov D, Chang MC, Chang P, Chen A, Cheon B, Chilikin K, Cho H, Cho K, Cho SJ, Choi SK, Choi Y, Choudhury S, Cinabro D, Cunliffe S, Das S, Dash N, De Pietro G, Dhamija R, Di Capua F, Dingfelder J, Doležal Z, Dong T, Epifanov D, Ferber T, Ferlewicz D, Fulsom B, Garg R, Gaur V, Gabyshev N, Giri A, Goldenzweig P, Golob B, Graziani E, Gu T, Gudkova K, Hadjivasiliou C, Hara T, Hayasaka K, Hayashii H, Hedges M, Higuchi T, Hou WS, Hsu CL, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jacobs W, Jang EJ, Jia S, Jin Y, Joo K, Kahn J, Kakuno H, Kaliyar A, Kawasaki T, Kiesling C, Kim C, Kim D, Kim KH, Kim K, Kim YK, Kinoshita K, Kodyš P, Konno T, Korobov A, Korpar S, Kovalenko E, Križan P, Kroeger R, Krokovny P, Kuhr T, Kumar M, Kumara K, Kuzmin A, Kwon YJ, Lai YT, Lalwani K, Lam T, Lange J, Laurenza M, Lee S, Li C, Li J, Li Y, Li Y, Li Gioi L, Libby J, Lieret K, Liventsev D, Martini A, Masuda M, Matsuda T, Matvienko D, Maurya S, Merola M, Metzner F, Miyabayashi K, Mizuk R, Mohanty G, Nakao M, Narwal D, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nisar N, Nishida S, Ogawa K, Ogawa S, Ono H, Onuki Y, Oskin P, Pakhlov P, Pakhlova G, Pang T, Pardi S, Park SH, Passeri A, Patra S, Paul S, Pedlar T, Pestotnik R, Piilonen L, Podobnik T, Popov V, Prencipe E, Prim M, Purohit M, Röhrken M, Rostomyan A, Rout N, Russo G, Sahoo D, Sandilya S, Sangal A, Santelj L, Sanuki T, Savinov V, Schnell G, Schwanda C, Seino Y, Senyo K, Sevior M, Shapkin M, Sharma C, Shebalin V, Shen C, Shiu JG, Singh J, Sokolov A, Solovieva E, Starič M, Stottler Z, Strube J, Sumihama M, Sumiyoshi T, Takizawa M, Tamponi U, Tanida K, Tenchini F, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Usov Y, Vahsen S, Van Tonder R, Varner G, Varvell K, Vinokurova A, Vossen A, Waheed E, Wang C, Wang MZ, Watanuki S, Won E, Yabsley B, Yan W, Yang S, Ye H, Yelton J, Yin J, Yuan C, Yusa Y, Zhai Y, Zhang Z, Zhilich V, Zhukova V. Search for the radiative penguin decays
B0→KS0KS0γ
in the Belle experiment. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.012006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
47
|
Martini A, Negri C, Bugarin L, Deplano G, Abasabadi RK, Lomachenko KA, Janssens TVW, Bordiga S, Berlier G, Borfecchia E. Assessing the Influence of Zeolite Composition on Oxygen-Bridged Diamino Dicopper(II) Complexes in Cu-CHA DeNO x Catalysts by Machine Learning-Assisted X-ray Absorption Spectroscopy. J Phys Chem Lett 2022; 13:6164-6170. [PMID: 35763262 PMCID: PMC9272442 DOI: 10.1021/acs.jpclett.2c01107] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Cu-exchanged chabazite is the catalyst of choice for NOx abatement in diesel vehicles aftertreatment systems via ammonia-assisted selective catalytic reduction (NH3-SCR). Herein, we exploit in situ X-ray absorption spectroscopy powered by wavelet transform analysis and machine learning-assisted fitting to assess the impact of the zeolite composition on NH3-mobilized Cu-complexes formed during the reduction and oxidation half-cycles in NH3-SCR at 200 °C. Comparatively analyzing well-characterized Cu-CHA catalysts, we show that the Si/Al ratio of the zeolite host affects the structure of mobile dicopper(II) complexes formed during the oxidation of the [CuI(NH3)2]+ complexes by O2. Al-rich zeolites promote a planar coordination motif with longer Cu-Cu interatomic distances, while at higher Si/Al values, a bent motif with shorter internuclear separations is also observed. This is paralleled by a more efficient oxidation at a given volumetric Cu density at lower Si/Al, beneficial for the NOx conversion under NH3-SCR conditions at 200 °C.
Collapse
Affiliation(s)
- Andrea Martini
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| | - Chiara Negri
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| | - Luca Bugarin
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
- European
Synchrotron Radiation Facility, 71 Avenue des Martyrs, CS 40220, 38043 Grenoble Cedex 9, France
| | - Gabriele Deplano
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| | - Reza K. Abasabadi
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| | - Kirill A. Lomachenko
- European
Synchrotron Radiation Facility, 71 Avenue des Martyrs, CS 40220, 38043 Grenoble Cedex 9, France
| | | | - Silvia Bordiga
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| | - Gloria Berlier
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| | - Elisa Borfecchia
- Department
of Chemistry and NIS Centre, University
of Turin, Via Giuria 7, 10125 Turin, Italy
| |
Collapse
|
48
|
Vojinovic J, Dehoorne J, Panaviene V, Susic G, Horneff G, Stanevicha V, Kobusinska K, Żuber Z, Dobrzyniecka B, Akikusa J, Avcin T, Martini A, Borlenghi C, Arthur E, Tatulych SY, Zang C, Tsekouras V, Vlahos B, Ruperto N. POS1293 TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundCLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in patients (pts) with juvenile idiopathic arthritis (JIA), categorized as extended oligoarticular JIA (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).ObjectivesEvaluation of the efficacy of ETN and its effect on health outcomes over 10 years of follow-up were secondary objectives and are reported here.MethodsPts (n=127) with eoJIA (n=60; 2-17 years of age), ERA (n=38; 12-17), or PsA (n=29; 12-17) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The study design has been reported previously.1 Efficacy endpoints included proportions of pts achieving JIA American College of Rheumatology (ACR) 30/50/70/90/100 criteria, Juvenile Arthritis Disease Activity Score (JADAS) inactive disease and clinical remission criteria, and sustained clinical remission (ACR criteria) or JADAS ≤1 for 12 continuous months (mths). Exploratory efficacy endpoints included time to flare following ETN withdrawal (based on ≥30% worsening in ≥3/6 ACR Pedi components, with ≥30% improvement in <2/6 remaining components and ≥2 active joints), and time to re-treatment with ETN.Observed Cases were used (i.e., there was no imputation for missing data) for pts who were in the Active Treatment Period.ResultsA total of 109/127 (86%) CLIPPER participants entered CLIPPER2 (n=55 eoJIA, n=31 ERA, n=23 PsA), with 99 (78%) pts continuing in the Active Treatment Period. Overall, 84 (66%) pts completed 120 mths of follow-up; 27 (21%) while actively taking ETN. Thirty (24%) pts entered the Withdrawal Period from the Active Treatment Period (i.e., they discontinued ETN, either by meeting the Wallace definition for clinically inactive disease for at least 6 months on ETN, or by having had a good clinical response and being deemed to benefit from withdrawal in the investigator’s judgment). Of the pts in the Active Treatment Period, over 90% achieved JIA ACR 50 response at all study time points. Sustained JADAS and ACR remission was achieved by 42 (33%) pts and 17 (13%) pts, respectively. The mean improvements from baseline in JADAS disease activity at mth 24 of CLIPPER were largely maintained through CLIPPER2 A total of 109/127 (86%) CLIPPER participants entered CLIPPER2 (n=55 eoJIA, n=31 ERA, n=23 PsA), with 99 (78%) pts continuing in the Active Treatment Period. Overall, 84 (66%) pts completed 120 mths of follow-up; 27 (21%) while actively taking ETN. Thirty (24%) pts entered the Withdrawal Period from the Active Treatment Period (i.e., they discontinued ETN, either by meeting the Wallace definition for clinically inactive disease for at least 6 months on ETN, or by having had a good clinical response and being deemed to benefit from withdrawal in the investigator’s judgment). Of the pts in the Active Treatment Period, over 90% achieved JIA ACR 50 response at all study time points. Sustained JADAS and ACR remission was achieved by 42 (33%) pts and 17 (13%) pts, respectively. The mean improvements from baseline in JADAS disease activity at mth 24 of CLIPPER were largely maintained through CLIPPER2.ConclusionThe low numbers of evaluable pts notwithstanding, efficacy results were consistent with the profile of ETN, and treatment responses were considered clinically meaningful and durable with long-term treatment.References[1]Foeldvari I, et al. Arthritis Res Ther 2019;21:125.[2]Trincianti C, et al. Arthritis Rheumatol 2021:73;1966-75.Trial Registration:NCT00962741/NCT01421069AcknowledgementsMedical writing support was provided by Iain McDonald, PhD, of Engage Scientific Solutions and was funded by Pfizer.Disclosure of InterestsJelena Vojinovic Speakers bureau: Abbvie, Roche, Sandoz, Joke Dehoorne Speakers bureau: Abbvie, Roche, Consultant of: Abbvie, Roche, Violeta Panaviene: None declared, Gordana Susic: None declared, Gerd Horneff Speakers bureau: Chugai, Eli-Lilly, Glaxo Smith and Kline, Janssen, Novartis, Pfizer, Roche and Sobi, Grant/research support from: Novartis, Janssen, Roche, Valda Stanevicha Speakers bureau: Sandoz, Abbvie, Roche, Katarzyna Kobusinska: None declared, Zbigniew Żuber: None declared, Bogna Dobrzyniecka: None declared, Jonathan Akikusa: None declared, Tadej Avcin Speakers bureau: AbbVie, Octapharma and Takeda, Consultant of: AbbVie, Octapharma and Takeda, Alberto Martini Speakers bureau: Aurinia, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Janssen, Pfizer, Roche, Consultant of: Aurinia, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Janssen, Pfizer, Roche, Cecilia Borlenghi Shareholder of: Pfizer, Employee of: Pfizer, Edmund Arthur Employee of: Pfizer, Svitlana Y Tatulych Shareholder of: Pfizer, Employee of: Pfizer, Chuanbo Zang Shareholder of: Pfizer, Employee of: Pfizer, Vasileios TSEKOURAS Shareholder of: Pfizer, Employee of: Pfizer, Bonnie Vlahos Shareholder of: Pfizer, Employee of: Pfizer, Nicolino Ruperto Speakers bureau: Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Idorsia, Janssen, Novartis, Pfizer, Sobi, UCB., Consultant of: Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Idorsia, Janssen, Novartis, Pfizer, Sobi, UCB.
Collapse
|
49
|
Vojinovic J, Dehoorne J, Panaviene V, Susic G, Horneff G, Stanevicha V, Kobusinska K, Żuber Z, Dobrzyniecka B, Akikusa J, Avcin T, Martini A, Borlenghi C, Arthur E, Tatulych SY, Zang C, Vlahos B, Ruperto N. POS0169 OPEN-LABEL, LONG-TERM (10-YEAR) STUDY OF THE SAFETY OF ETANERCEPT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundCLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in the treatment of patients (pts) with juvenile idiopathic arthritis (JIA) categorized as extended oligoarticular arthritis (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).ObjectivesThe objective of this analysis was to describe the safety of ETN in this population after 10 years of follow up.MethodsPts (n=127) with eoJIA (2-17 years), ERA, or PsA (each 12-17 years) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The primary outcome measure was the occurrence of malignancy. Long-term safety was assessed as the total incidence of events from CLIPPER baseline (BL) to month (mth) 120, frequency of events per 100 patient-years (EP100PY), and frequency of events in each study year.ResultsA total of 109/127 (86%) pts entered CLIPPER2; 99 (78%) continued in the active treatment period. At mth 120, 84 (66%) pts had completed the study; 27 (21%) while actively taking ETN; 7 (6%) had withdrawn from treatment due to low/inactive disease; 5 (4%) had re-started ETN following an earlier withdrawal from treatment; and 45 (35%) had stopped ETN (but remained under observation); 25 (20%) pts permanently discontinued from the CLIPPER2 study. In CLIPPER/CLIPPER2, 1 case of malignancy (Hodgkin’s disease) was reported (1 pt with eoJIA in Year 3). There was 1 case of uveitis (1 pt with eoJIA in Year 8) and 3 of Crohn’s disease (2 pts with ERA, Year 1/Year 6; 1 pt with eoJIA, Year 5). There were 2 cases of opportunistic infections (both herpes zoster), and no deaths. Overall, there were 559 (81.82 EP100PY) treatment-emergent adverse events (TEAEs) excluding infections and injection-site reactions (ISRs). The overall rate of TE serious infections was low (N=14; 2.05 EP100PY) (Table 1), with the most common TE serious infection being gastroenteritis (N=2; 0.29 EP100PY). The most frequently reported TEAEs (N [EP100PY]) were headache (28 [4.10]), arthralgia (24 [3.51]), pyrexia (21 [3.07]), diarrhea (14 [2.05]), and leukopenia (12 [1.76]). Overall, 39 patients reported serious AEs (excluding infections/ISRs). The number and frequency (N [EP100PY]) of TEAEs (excluding infections/ISRs) decreased over the 10-year study period from 193 [173.81] in Year 1 to 9 [27.15] in Year 10. The number and frequency of TE infections and TE serious infections also decreased over the 10-year study period. There was no clear trend of a decrease over time for the incidence of TE serious AEs (Figure 1).Table 1.ETN Safety Summary (from CLIPPER BL to mth 120), N (EP100PY) (FAS)*eoJIA, n=60(EXP=313.667 PY)ERA, n=38(EXP=206.971 PY)PsA, n=29(EXP=162.576 PY)Total, n=12(EXP=683.214 PY)TEAEs†269 (85.76)176 (85.04)114 (70.12)559 (81.82)TE serious AEs†16 (5.10)17 (8.21)7 (4.31)40 (5.85)TE ISRs23 (7.33)29 (14.01)12 (7.38)64 (9.37)TE infections418 (133.26)99 (47.83)155 (95.34)672 (98.36)TE serious infectionsǂ5 (1.59)4 (1.93)5 (3.08)14 (2.05)Opportunistic infections§01 (0.48)1 (0.62)2 (0.29)TEAEs causing withdrawal†7 (2.23)9 (4.35)2 (1.23)18 (2.63)TE infections causing withdrawal2 (0.64)01 (0.62)3 (0.44)*While on active ETN treatment or within 30 days of last dose†Excluding infections/ISRsǂGastroenteritis, 2 (0.29); acute tonsillitis, anal abscess, bronchopneumonia, gastrointestinal infection, helicobacter gastritis, influenza, peritonitis, pharyngitis, pyelocystitis, sepsis, urinary tract infection, viral infection, all 1 (0.15)§Both herpes zosterEXP, exposure to ETN; FAS, full analysis set; n, number of patients; N, number of eventsConclusionETN treatment to mth 120 was well tolerated in this patient population and consistent with the known safety profile. Frequency of TEAEs and TE infections decreased over time. Over 10 years, there was 1 reported event of malignancy and the overall rate of TE serious infections was low.References[1]NCT00962741/NCT01421069AcknowledgementsMedical writing support was provided by Iain McDonald, PhD, of Engage Scientific Solutions and was funded by Pfizer.Disclosure of InterestsJelena Vojinovic Speakers bureau: Abbvie, Roche, Sandoz, Joke Dehoorne Speakers bureau: Abbvie, Roche, Consultant of: Abbvie, Roche, Violeta Panaviene: None declared, Gordana Susic: None declared, Gerd Horneff Speakers bureau: Chugai, Eli-Lilly, Glaxo Smith and Kline, Janssen, Novartis, Pfizer, Roche and Sobi, Grant/research support from: Novartis, Janssen, Roche, Valda Stanevicha Speakers bureau: Sandoz, Abbvie, Roche, Katarzyna Kobusinska: None declared, Zbigniew Żuber: None declared, Bogna Dobrzyniecka: None declared, Jonathan Akikusa: None declared, Tadej Avcin Speakers bureau: AbbVie, Octapharma, and Takeda, Consultant of: AbbVie, Alexion, Octapharma, and Takeda, Alberto Martini Speakers bureau: Aurinia, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Janssen, Pfizer, Roche, Consultant of: Aurinia, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Janssen, Pfizer, Roche, Cecilia Borlenghi Shareholder of: Pfizer, Employee of: Pfizer, Edmund Arthur Employee of: Pfizer, Svitlana Y Tatulych Shareholder of: Pfizer, Employee of: Pfizer, Chuanbo Zang Shareholder of: Pfizer, Employee of: Pfizer, Bonnie Vlahos Shareholder of: Pfizer, Employee of: Pfizer, Nicolino Ruperto Speakers bureau: Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Idorsia, Janssen, Novartis, Pfizer, Sobi, UCB., Consultant of: Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Idorsia, Janssen, Novartis, Pfizer, Sobi, UCB.
Collapse
|
50
|
Ruperto N, Chertok E, Dehoorne J, Horneff G, Kallinich T, Louw I, Compeyrot-Lacassagne S, Lauwerys B, Martin N, Marzan K, Knibbe W, Martin R, Zhu X, Whelan S, Pricop L, Martini A, Lovell DJ, Brunner H. OP0221 EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA). Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundEnthesitis-related Arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA) characterised by heterogeneous and insidious manifestations comprising axial and/or peripheral arthritis, and enthesitis.1 Secukinumab (SEC) demonstrated efficacy and safety in both ERA and juvenile psoriatic arthritis (JPsA) in the JUNIPERA trial.2ObjectivesTo evaluate the rate of flare risk reduction and efficacy of SEC on axial and peripheral manifestations in patients (pts) with active ERA.MethodsERA pts (2 to <18 years of age) with active disease (both ≥3 active joints and ≥1 active enthesitis site) were included. In the open-label (OL) treatment-period (TP)1, s.c. SEC (75/150 mg in pts <50/ ≥50 kg) was administered at baseline (BL), and at Week (Wk) 1–4, 8 and 12. Pts who achieved at least JIA-ACR30 response at Wk 12 were randomised into the double-blinded TP2 to continue SEC or placebo (PBO) every 4 wk until a disease flare, or up to Wk 100. The primary endpoint was time to flare in ERA and JPsA pts. The juvenile spondyloarthritis disease activity Index (JSpADA) is a disease activity assessment tool that contains 8 items to measure axial and peripheral disease activity.3 Evaluation of axial and peripheral manifestations at the end of TP1 and TP2 in pts who experienced these symptoms at BL included modified Schober test (lumbar flexion), inflammatory back pain, FABER (Flexion, ABduction, External Rotation) test, JIA-ACR responses, Juvenile Arthritis Disease Activity Score (JADAS)-27, and resolution of enthesitis and dactylitis for peripheral disease. These outcomes were also used to assess JIA disease course at the end of TP2.ResultsA total of 52/86 (60.5%) pts with ERA were enrolled in the OL period TP1 (mean age, 13.7 years; male, 78.8%). In total, 51/52 (98.1%) pts completed TP1 and 41/44 (93.2%) completed TP2. At BL, mean JADAS-27 was 14.8, mean JSpADA index was 3.9, mean enthesitis and dactylitis counts were 2.7 and 0.4, respectively, mean number of active joints was 6.2 and of mean joints with limited range of motion 4.9. The relative risk reduction of experiencing a disease flare in TP2 was 55% (HR 0.45, 95% CI: 0.16–1.28, p=0.075) in ERA pts (Figure 1). The overall axial and peripheral disease symptoms improved over time and are presented in the Table 1. At the end of TP1, 84.6% (44/52) of pts achieved JIA-ACR 30 and 65.4% (34/52) achieved JIA-ACR 70. Clinically relevant reduction of functional ability as assessed by Childhood Health Assessment Questionnaire (CHAQ) also occurred (see Table 1).Table 1.Resolution of axial and peripheral disease symptoms and JIA ACR responses at the end of TP1 and 2Clinical response, mean (SD) change from BL (unless otherwise stated)TP1-Wk 12End of TP2*SEC (N=52)SEC (N=22)PBO (N=22)JSpADA index−2.4 (1.7)−2.7 (1.7)−2.3 (2.1)JSpADA Schöber, %58.3100.0100.0Inflammatory back pain, %77.8100.050.0FABER test, %52.6100.083.3Clinical sacroiliitis, %53.3100.050.0Enthesitis−2.2 (1.9)−2.5 (2.1)−1.3 (1.8)Dactylitis−0.2 (0.8)−0.2 (1)−0.1 (0.4)JIA ACR30, %84.690.968.2JIA ACR50, %78.881.868.2JIA ACR70, %65.468.254.5JIA ACR90, %32.745.550.0JIA ACR100, %26.936.445.5Inactive disease, %38.550.050.0CHAQ−0.5 (0.5)−0.6 (0.7)−0.4 (0.5)CRP, median (SD) change from BL−1.8 (38.7)−5.8 (38.3)0 (35.9)JADAS-27−9.6 (7.5)−11.0 (8.9)−7.6 (8.9)Resolution of enthesitis#, %72.378.683.3Resolution of dactylitis#, %5066.70*End of TP2 is based on individual pts’ last visit at TP2. #At BL, in TP1, enthesitis (n= 46); dactylitis (n=5). In TP2, no. of pts who had presence at BL and showed complete resolution at the end of TP2: enthesitis, SEC 14, PBO 18; dactylitis, SEC 3, PBO, 0. CRP, C-reactive proteinConclusionIn pts with ERA, SEC demonstrated longer time to disease flare vs PBO and exhibited rapid and sustained improvement of axial and peripheral manifestations up to Wk 104.References[1]Pagnini I, et al. Front Med 2021;8:6673052.[2]Brunner H, et al. Arthritis Rheumatol 2021;73 (suppl 10).[3]Weiss PF, et al. Arthritis Care Res 2014;66:1775-82.Disclosure of InterestsNicolino Ruperto Speakers bureau: Eli Lilly, GlaxoSmith and Kline, Pfizer, SOBI and UCB, Paid instructor for: Eli Lilly and Pfizer, Consultant of: Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Celegene, Domain therapeutic, Eli Lilly, EMD Serono, GlaxoSmith and Kline, Idorsia, Janssen, Novartis, Pfizer, SOBI and UCB, Grant/research support from: Bristol Myers and Squibb, Eli Lilly, F Hoffmann-La Roche, Novartis, Pfizer and SOBI, Elena Chertok: None declared, Joke Dehoorne Speakers bureau: Abbvie, Roche, Consultant of: Abbvie, Roche, Pfizer, Grant/research support from: Abbvie, Roche, Gerd Horneff Speakers bureau: Novartis, Pfizer, Janssen, Grant/research support from: Pfizer, Novartis, Roche, MSD, Tilmann Kallinich Speakers bureau: Roche, Ingrid Louw Speakers bureau: Pfizer, Abbvie, BMS, Consultant of: Pfizer, Abbvie, Janssen, Amgen and Cipla, Sandrine Compeyrot-Lacassagne: None declared, Bernard Lauwerys Employee of: UCB Pharma, Neil Martin: None declared, Katherine Marzan Grant/research support from: Novartis, Sanofi, William Knibbe Speakers bureau: Novartis, Amgen, UCB, Abbvie, Ruvie Martin Shareholder of: Novartis, Employee of: Novartis, Xuan Zhu Shareholder of: Novartis, Employee of: Novartis, sarah whelan Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Alberto Martini Speakers bureau: Aurinia, Bristol Myers and Squibb, Eli Lilly, EMD, Janssen, Pfizer, Roche and Serono, Consultant of: Aurinia, Bristol Myers and Squibb, Eli Lilly and EMD, Daniel J Lovell Consultant of: Astra Zeneca, Boehringer Ingelheim, GSK, Hoffman LaRoche, Novartis, UBC, Grant/research support from: Astra Zeneca, Boehringer Ingelheim, GSK, Hoffman LaRoche, Novartis, UBC, Hermine Brunner Consultant of: Novartis, Grant/research support from: Novartis
Collapse
|